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ABBREVIATIONS 
 
3
H–Dex tritiated Dexamethasone 
AAA  P548A/T549A/V551A mutant of rat GR 
ACTH  Adrenocorticotropin 
BSA  Bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
Cdc2  Cell division cycle protein 2 homolog 
CTD  C–terminal domain of Hsp90 
DAB  3,3’–Diaminobenzidine 
DAPI  4,6–Diamidino–2–phenylindole 
DDW  Double distilled water 
Dex  Dexamethasone 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethyl sulfoxide 
DTT  Dithiothreitol 
EDTA  Ethylenediaminetetraacetic acid 
FCS  Fetal calf serum 
Gc  Glucocorticoid 
GR  Glucocorticoid receptor 
H2O2  Hydrogen peroxide 
HEPES 2–(4–(Hydroxyethyl)–1–piperazinyl)–ethanolsulforic acid 
Hsp90  Heat shock protein 90 
ICC  Immunocytochemistry 
IHC  Immunohistochemistry 
kD  Kilodalton (molecular weight) 
MD  Middle domain of Hsp90 
NaCl  Sodium chloride 
NaOH  Sodium hydroxide 
NP–40  Nonidet P–40 
NTD  N–terminal domain of Hsp90 
ON  Over night 
ONPG  o–Nitrophenyl–β–D–galactopyranosid 
PEG  Polyethylene glycol 
PBS  Phosphate buffered saline 
PVDF  Polyvinylidene fluoride 
RT  room temperature 
SDS  Sodium dodecyl sulphate 
SDS–PAGE SDS polyacrylamid gel electrophoresis 
TEMED Tetramethylethylenediamine 
TBS  Tris buffered saline 
TBST  TBS with 0.1% Tween–20 
WT  Wild type 
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1 SUMMARY 
 
The main function of glucocorticoids in corticotroph cells is to suppress proopiomelanocortin, 
the precursor of the stress hormone adrenocorticotropin (ACTH). Cushing’s disease is a rare 
but severe neuroendocrine condition caused by partially glucocorticoid resistant corticotroph 
adenomas, which consequently secrete excessive amounts of ACTH in an uncontrolled 
fashion. The patients suffer from chronic hypercortisolism due to excessive stimulation of the 
adrenal glands by ACTH to produce glucocorticoids. Impairing mutations of the 
glucocorticoid receptor (GR) only sporadically explain the reduced glucocorticoid sensitivity 
in the adenomas – the molecular mechanism behind the partial resistance is poorly 
understood. 
The function of GR depends on direct interactions with the molecular chaperone Hsp90. Both 
the reduction and overexpression of Hsp90 impedes GR activity in different experimental 
settings. Therefore, the expression of the inducible Hsp90α isoform was determined in biopsy 
specimens of corticotroph pituitary adenomas from patients with Cushing’s disease. Its strong 
overexpression compared to normal human pituitary cells paved the way to study its role in 
the function of corticotroph adenomas using small molecules which target Hsp90. 
The three distinct Hsp90 inhibitors 17–AAG, Novobiocin and Silibinin showed 
antiproliferative effects in AtT–20 cells through the degradation of the oncogenic client 
kinase Cdc2, a hallmark of pharmacologic inhibition of Hsp90. Surprisingly, only the N–
terminal Hsp90 inhibitor 17–AAG caused the degradation of GR, as was reported also for 
other Geldanamycin–based Hsp90 inhibitors. Neither Silibinin nor the C–terminal Hsp90 
inhibitor Novobiocin affected GR protein levels. These converging effects led to the 
assumption that both compounds bind to the same domain in Hsp90. It was shown here that 
Novobiocin displaces Silibinin from the C–terminal domain of Hsp90, and that these 
compounds dissociate mature GR from Hsp90 at the biochemical level. As a result, increased 
levels of mature receptor were present in the cell able to bind glucocorticoids with high 
affinity. This novel molecular mechanism proved to potentiate GR transcriptional activity in 
AtT–20 cells. The potentiation in GR activity also led to enhanced suppression of ACTH 
elicited by low concentrations of Dexamethasone in AtT–20 cells and in primary cultures of 
human corticotroph adenomas from patients with Cushing’s disease. In contrast, Silibinin did 
not show effects on rat normal pituitary cells. Finally, Silibinin reduced tumor growth, 
partially reverted hormonal alterations, and alleviated symptoms in a mouse allograft model 
for Cushing’s disease. 
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These results suggest that the regulation of GR sensitivity by overexpressed Hsp90 may 
represent a pharmacologically reversible mechanism in the pathogenesis of this disease. 
Together, a proof of principle is provided that the clinically safe Hsp90 inhibitor Silibinin 
potentially restores glucocorticoid sensitivity in corticotroph adenomas in vitro and in vivo, 
and that it might be used to treat Cushing’s patients in the future. 
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2 ZUSAMMENFASSUNG 
 
Die zentrale Funktion von Glukokortikoiden in kortikotrophen Zellen ist die Supprimierung 
von Proopiomelanokortin, dem Vorgänger des Stresshormons Adrenokortikotropin. Morbus 
Cushing ist eine seltene neuroendokrinologische Erkrankung, die durch partiell 
Glukokortikoid–resistente kortikotrophe Adenome der Adenohypophyse verusacht werden. 
Die exzessive Produktion und Sekretion von Adrenokortikotropin führt zu exzessiver 
Stimulation der Nebenierenrinde zur Produktion von Glukokortikoiden, und die Patienten 
leiden unter chronischem Hyperkortisolismus. Mutationen in dem Gen, das für den 
Glukokortikoidrezeptor (GR) codiert, können die Glukokortikoidresistenz nur in seltenen 
Fällen erklären – der molekulare Mechanismus, der zu der partiellen Resistenz führt, ist nur 
wenig verstanden. 
Das molekulare Chaperon Hsp90 essenziell für die Funktion des GR – sowohl stark reduzierte 
Proteinlevel von Hsp90 als auch dessen Überexpression inhibieren die Aktivität des GR in 
experimentellen Ansätzen. Somit wurde die Expression der induzierbaren Hsp90α–Isoform in 
Biopsieschnitten kortikotropher Adenome von Patienten mit Morbus Cushing bestimmt. Die 
ausserordentlich starke Überexpression in adenomatösen Gewebe im Vergleich zu gesunden 
Hypophysenzellen hat es ermöglicht, die Rolle von Hsp90 in der Funktion kortikotropher 
Adenome durch spezifische Inhibitoren zu untersuchen. 
Die drei strukturell unterschiedlichen Hsp90–Inhibitoren 17–AAG, Novobiocin und Silibinin 
zeigten wachstumshemmende Wirkung in AtT–20 Zellen. Diese Effekte gingen mit der 
Degradation der onkogenen Klientenkinase Cdc2 einher, ein charakteristisches Merkmal für 
die pharmakologische Inhibition von Hsp90. In Übereinstimmung mit der Literatur führte der 
auf Geldanamyin basierende, N–terminale Hsp90–Inhibitor 17–AAG zur Degradation des 
Klientenproteins GR. Überraschenderweise wurde das Proteinlevel des GR weder durch 
Silibinin noch durch den C–terminalen Hsp90–Inhibitor Novobiocin beeinträchtigt. Dieser 
Effekt liess vermuten, dass beide Inhibitoren an die selbe Domäne in Hsp90 binden. Es 
konnte gezeigt werden, dass Novobiocin an Hsp90 gebundenes Silibinin verdrängt, und dass 
die niedermolekularen Verbindungen die Freilassung des GR auf biochemischer Ebene 
bedingen. Das führte zu erhöhter Verfügbarkeit von reifem GR in der Zelle, der 
Glukokortikoid mit hoher Affinität binden konnte. Dieser neuartige, molekulare Mechanismus 
resultierte in der Potenzierung der transkriptionellen Aktivität des GR. Durch die verstärkte 
GR–Aktivität wurde die Supprimierung von Adrenokortikotropin sowohl in AtT–20 Zellen 
als auch in Primärkulturen humaner, kortikotropher Adenome verstärkt. Im Gegensatz hierzu 
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hatte Silibinin keine Wirkung auf normale Ratten–Hypophysenzellen in Kultur. Letztlich 
zeigte Silibinin antitumorigene Effekte in einem Maus–Allograftmodell für Morbus Cushing. 
Auch konnte in diesem Modell eine partielle Unterdrückung der hormonellen Veränderungen 
erzielt werden, was mit der Reduktion krankheitsbedingter Symptome einherging. 
Diese Ergebnisse deuten auf einen pathogentischen Mechanismus des stark überexprimierten 
Hsp90 hin, der pharmakologisch reversibel ist. Somit könnte der klinisch sichere Hsp90–
Inhibitor Silibinin in Zukunft eine Behandlungsmethode von Patienten mit Morbus Cushing 
darstellen. 
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3 AIM OF THE STUDY 
 
The molecular chaperone Hsp90 is a validated target in cancer therapy. Furthermore, Hsp90 
directly regulates the function of GR. Cushing’s disease is caused by corticotroph adenomas 
in which the GR displays a partial resistance towards glucocorticoids. To date, the pathogenic 
mechanism that underlies the glucocorticoid resistance in this malignancy is scarcely 
understood. 
The aim of the present work was to investigate the hypothesis that abnormal expression or 
activity of Hsp90 may cause the reduced hormone responsiveness in corticotroph adenomas. 
The initial finding that Hsp90 is strongly overexpressed in this malignancy compared to 
normal human pituitary tissue opened the possibility to investigate its role using distinct 
classes of specific inhibitors. In the AtT–20 cellular model, the effects of the Hsp90 inhibitors 
on proliferation and hormone production were characterized. The most promising Hsp90 
inhibitor was used to study its effects in primary cultures of human corticotroph adenomas, 
and its possible influence on normal pituitary cell function in vitro. Finally, the mouse 
allograft model for Cushing’s disease was chosen to attempt a proof of principle for the 
pharmacologic treatment of patients with this severe neuroendocrine condition. 
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4 INTRODUCTION 
 
4.1 THE ADENOHYPOHYSIS AND CORTICOTROPH ADENOMAS 
 
THE ANTERIOR LOBE OF THE PITUITARY 
The adenohypophysis is a major organ of the endocrine system and regulates physiological 
processes such as stress, growth, reproduction, and lactation. The gland has a diameter of 
approximately 1 cm in adults and is located within a bony depression of the sphenoid bone 
called the sella turcica, right below the optic chiasma. During development, upon 
differentiation and proliferation cells of the anterior wall of the Rathke’s pouch give rise to 
the adenohypophysis. Specialized cells of this organ, when fully developed, produce six 
hormones: Growth hormone (GH), prolactin, (PRL), follicle stimulating hormone (FSH), 
luteinizing hormone (LH), thyroid stimulating hormone (TSH), and adrenocorticotropin 
(ACTH) to be released into the bloodstream where they fulfil their role as stimulators of target 
tissues (Asa and Ezzat, 1998). Corticotrophs is the particular cell type that secretes ACTH and 
constitutes the central switchpoint of the stress hormone axis. In healthy humans, both 
stimulatory and repressive mechanisms acting on this cell type facilitate the stress response as 
well as the reconstitution of homeostasis through intricate regulation of ACTH production and 
release. 
 
THE STRESS HORMONE AXIS 
The hypothalamic–pituitary–adrenal axis (HPA axis) is an integrated multilevel system, 
responsive to environmental as well as endogenous events, with glucocorticoids (Gcs) being 
the executive factor and the direct indicator of its activity. The HPA axis enables the organism 
to adapt to changing demands via the adjustment of metabolic activity on a global scale in 
order to deal with these events. After the brain has processed stressful situations, such as 
encounters with predators or an applicant having a job interview, the stress axis will be 
stimulated – an increase in energy expenditure is expected in order to deal with situations 
perceived as threatening. Increased energy, however, is provided on the expense of other 
physiological processes, and homeostasis has to be restored as soon as possible. The 
functional HPA axis is composed of hypothalamic secretory cells for the synthesis and 
secretion of corticotrophin releasing hormone (CRH); a hypothalamic pituitary portal system 
– which is not protected by the blood brain barrier – for the transport of CRH; corticotroph 
cells of the adenohypophysis expressing the CRH receptor and which are able to process 
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proopiomelanocortin (POMC) into ACTH for release into the bloodstream; and an ACTH–
responsive adrenal cortex to induce the synthesis and release of Gcs (Tsigos and Chrousos, 
2002). Gcs have pleiotropic and cell type specific effects, elicited by their molecular target, 
the ubiquitously expressed glucocorticoid receptor (GR). They influence metabolic activities, 
the immune system, development, and arousal (Kadmiel and Cidlowski, 2013). It is a 
remarkable, yet an omnipresent, scheme in biology that a certain effector of stimulating nature 
simultaneously downregulates its own activity through direct interference with central 
switchpoints of the pathway it activates: Gcs elicit negative feedback loops on the HPA axis, 
both centrally and at the pituitary level in corticotroph cells, to prevent overshooting of the 
stress response as well as to restore homeostasis (Fig. I – Stress response). 
Corticotroph cells express POMC under the control of the lineage specific transcription factor 
Tpit (Pulichino et al., 2003). Tpit acts in concert with Pitx to ensure constitutive expression of 
POMC (Lamolet et al., 2001). In this cell type, POMC is enzymatically cleaved mainly into 
ACTH to be secreted into the bloodstream (Bertagna, 1994). Under stress, hypothalamic CRH 
(and also arginine–vasopressin) leads to enhanced production of ACTH through activation of 
their respective receptor on corticotroph cells – the CRH receptor (and the arginine–
vasopressin receptor) (Tsigos and Chrousos, 2002; Vale et al., 1981). The CRH receptor is a 
G–protein coupled receptor which is linked to the Gαs–subunit of G–proteins. The binding of 
CRH elicits an intracellular signalling cascade via the adenylate cyclase and subsequently 
protein kinase A (PKA) (Hemley et al., 2007). PKA then activates the transcription factor 
Nur77 to enhance POMC production (Kovalovsky et al., 2002; Maira et al., 2003; Philips et 
al., 1997a). The central mechanism for the restoration of homeostasis after stress has waned 
off is the negative feedback loop of GR at two levels: First, in the hypothalamus, CRH is 
suppressed to reduce the stimulation of hypohyseal ACTH production (McEwen, 2007). 
Second and most importantly, GR suppresses POMC gene activity in corticotroph cells, a 
mechanism called trans–repression, which involves the masking of Nur77 to compact the 
chromatin structure of the POMC gene via recruitment of corepressors (Philips et al., 1997b; 
Bilodeau et al., 2006).  
Controlling the systemic level of ACTH is essential, since it stimulates the adrenal glands to 
produce Gcs. When the intricate regulatory mechanisms of the stress hormone axis do not 
function, life threatening hypercortisolism can arise – a condition commonly designated as 
Cushing’s syndrome. Cushing’s syndrome can be caused by adenocarcinomas of the adrenal 
glands which excessively produce Gcs independent of stimulation through circulating ACTH. 
Pathologically elevated levels of ACTH can also be caused by ectopic ACTH producing 
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tumors (such as subtypes of lung cancer) (Tritos et al., 2011). However, Cushing’s disease is 
the most common cause of Cushing’s syndrome, and it is exclusively caused by corticotroph 
adenomas (Newell-Price et al., 1998). 
 
ADENOMAS OF THE ANTERIOR PITUITARY 
Pituitary adenomas constitute up to 15% of intracranial neoplasms, and include those that 
secrete ACTH (Cushing’s disease), GH (acromegaly), PRL (prolactinoma), TSH 
(hyperthyroidism), and gonadotroph tumors which are mostly non–secreting adenomas. 
Although growth patterns are not consistently predictable, these monoclonal expansions 
exhibit a unique and invariably benign proliferative advantage. Tissue invasion and 
metastases rarely occur. They are associated with severe clinical symptoms due to excessive 
hormone production or the ability of non–secreting tumors to smother normal pituitary 
function, which results in a form of hypopituitarism (i.e., lack of pituitary hormones) 
(Melmed, 2011). The present work focuses on corticotroph adenomas, which excessively 
secrete ACTH. 
 
CORTICOTROPH ADENOMAS CAUSE CUSHING’S DISEASE 
With an incidence of 80 patients per year and an overall prevalence of approximately 
1:100.000 in Germany, Cushing’s disease is a rare but severe neuroendocrine condition in 
which the patients suffer from chronic hypercortisolism caused by corticotroph adenomas. 
The chronic hypercortisolism causes numerous symptoms such as hypertension, diabetes 
mellitus, obesity, osteoporosis, myopathy, psychiatric and immune disturbances, and the 
disease displays with high morbidity and mortality if left untreated (Newell-Price et al., 
2006). Treatment of choice is transphenoidal surgery, and if conducted by an experienced 
surgeon, between 70 to 90% of the patients do not relapse over a period of ten years (Tritos et 
al., 2011). If the adenoma cannot be located due to its small size (microadenoma), in case of 
relapse, or if the patient cannot be indicated for surgery due to health problems caused by the 
chronic hypercortisolism, available treatment options are suboptimal. Radiation therapy 
presents with a latency period of approximately two years until beneficial effects occur. 
During that time, the patient requires anti–glucocorticoids (mifepristone) or steroid synthesis 
inhibitors (ketoconazole) to counter the hypercortisolism. Irradiation may result in the 
development of hypopituitarism due to collateral damage inflicted on the surrounding healthy 
pituitary tissue (Vance, 2009). An extreme measure for patients whose life is imminently 
threatened by the excessive ACTH secretion of the adenoma would be bilateral 
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adrenalectomy, followed by lifelong Gc–supplementation. However, in up to 50% of the 
cases, bilateral adrenalectomy results in the development of a Nelson tumor, a very aggressive 
type of corticotroph pituitary adenomas (Barber et al., 2010). Lastly, and frequently 
administered since its approval by the Federal Drug Agency in 2013, the somatostatin analog 
pasireotide is available. In approximately 25% of the patients, it leads to normalization of 
blood ACTH through direct action on somatostatin receptors expressed on corticotroph 
adenomas. However, severe side effects are observed in the patients which have to be 
combated with additional medication (Colao et al., 2012). Altogether, a safe and efficacious 
medication which targets the pituitary adenoma is needed. 
The central pathogenetic mechanism of corticotroph adenomas is their partial Gc–resistance: 
Only high doses of the synthetic GR–agonist Dexamethasone (Dex) result in the suppression 
of systemic ACTH in the patients, while the strongly elevated circulating Gc–levels do not 
(Arnaldi et al., 2003). Thus, GR is expressed in the adenomas, but it can only signal in the 
presence of very high concentrations of agonist. Mutations of NR3C1, the gene encoding GR, 
have only sporadically been found in the Gc–resistant adenomas, and thus cannot explain the 
reduced sensitivity of GR (Lamberts, 2002). To date, a comprehensive understanding of the 
molecular mechanism that causes the partial Gc–resistance is lacking. 
As a basis for the work presented here, it was hypothesized that Hsp90, a direct regulator of 
GR function, might be involved in the partial Gc–resistance of corticotroph adenomas (Fig. I 
– Cushing’s disease). 
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Figure I – Role of GR in the negative feedback loop of ACTH production in health and in 
patients with Cushing’s disease. Hypothalamic and corticotroph GR senses bloodborne Gc–levels for 
the suppression of HPA axis activity to prevent overshooting of the stress response and to restore 
homeostasis after stress withdrawal. In Cushing’s disease, partially Gc–resistant corticotroph 
adenomas fail to suppress ACTH. The patients suffer from life threatening hypercortisolism which 
acts on the sensitive organs. Detrimental mutations of GR only explain sporadic cases of the Gc–
resistance, and the molecular mechanism underlying the hormone resistance is scarcely understood. 
The molecular chaperone Hsp90 ultimately regulates GR function through direct interaction with the 
receptor at multiple stages during hormone transmission. It was hypothesized here that abnormal 
Hsp90 function causes the greatly reduced hormone responsiveness in corticotroph adenomas. 
 
 
4.2 HSP90 IN HEALTH AND DISEASE 
 
CHAPERONES IN PROTEIN FOLDING 
Since the onset of molecular biology, the question of how proteins adopt their functional 
conformation in a living cell has puzzled researchers. It is clear that the laws of 
thermodynamics fold a protein into a conformation according to its amino acid sequence. But 
the crowded environment of a cell promotes intermolecular interactions, thus introducing 
random forces to folding events (Ellis, 2007). This would result in uncontrollable outcomes, 
and the cell as a highly organized system cannot exist under such conditions. Hence, factors 
that ensure guided folding are necessary. 
Proteins are optimized through evolution to be only marginally stable at the respective growth 
temperature of an organism. Even for forms of life that thrive at extreme temperatures, a small 
increase in temperature can cause protein unfolding, entanglement, and unspecific 
aggregation: Proteostasis is disturbed and puts a severe threat to survival. Thus, the 
deleterious aggregation of unfolded proteins triggers counter measures: The expression of 
members of the heat shock family such as chaperones and protein remodelling factors called 
chaperonins (Richter et al., 2010). These specialized proteins facilitate the folding of newly 
synthesized proteins and the refolding of misfolded proteins into their active conformation, 
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aid in assembly and disassembly of macromolecular complexes, target terminally misfolded 
proteins to degradation via the proteasome, and interact with transport machineries to guide 
proteins to their proper locations (Zou et al., 2008; McClellan et al., 2005; Young et al., 
2003). Hsp90 (heat shock protein 90) fulfills all aspects of a typical heat shock protein under 
proteotoxic stress (Hartl and Hayer-Hartl, 2009). In addition, it is essential for the function of 
numerous so–called client proteins – a specific subset of proteins which constitute central 
regulators of homeostasis, both under normal and pathologic conditions. 
 
HEAT SHOCK PROTEIN 90 
Hsp90 is conserved from bacteria to mammals. In mammals, four paralogs constitute the 
Hsp90–family: Hsp90α and Hsp90β in the cytoplasm, Grp94 in the endoplasmatic reticulum 
and TRAP1 in the mitochondrial matrix (Sreedhar et al., 2004). The cytoplasmatic alpha and 
beta isoforms arouse by gene duplication roughly 500 million years ago (human Hsp90α: 
HSP90AA1 chromosome 14q32.33; human Hsp90β: HSP90AB1 chromosome 6p12). Very 
early in eukaryotic evolution, Grp94 originated from a paraloguous gene duplication (human 
Grp94: HSP90B1 chromosome 12q24.2-q24.3), while TRAP1 (human TNF receptor 
associated protein 1: TRAP1 chromosome 16p13.3) is the product of a very recent gene 
rearrangement of Hsp90α (Gupta, 1995; Grammatikakis et al., 2002). Although Hsp90α and 
Hsp90β have 85% sequence identity, and are ubiquituously expressed, there are functional 
differences unique to each isoform. First, Hsp90α is considered to be highly inducible, but 
also the constitutive Hsp90β isoform can be enhanced upon sensing of cellular stress (heat 
shock response) (Richter et al., 2010). This mechanism mainly involves the upregulation of 
heat shock proteins as well as anti–apoptotic factors through dissociation – and subsequent 
activation – of heat shock transcription factors (HSFs) from Hsp90 itself (Zou et al., 1998). 
Hsp90α regulates muscle cell differentiation in zebrafish, and certain aspects of the cell cycle 
as well as apoptosis (Nakai and Ishikawa, 2001; Lele et al., 1999; Solier et al., 2012). Mice 
which are homozyguous for a non–functional Hsp90β mutant die during embryogenesis due 
to a failure in the induction of a placental labyrinth, and the β–isoform displays highly 
regulated expression patterns during early embryogenesis (Gruppi et al., 1991; Vanmuylder et 
al., 2002). Furthermore, the two cytosolic isoforms differ in such that they can more or less 
efficiently chaperone client proteins in yeast, whereas only Hsp90β renders cells sensitive to 
the N–terminal Hsp90 inhibitor Radicicol (Millson et al., 2007). In sum, diverging functional 
roles can be attributed to the cytoplasmatic isoforms, but clear distinctions are difficult to 
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observe due to their compensatory activities. Considering that the work conducted herein has 
exclusively dealt with the cytoplasmatic proteins, Grp94 and TRAP1 will not be discussed. 
Hsp90 consists of three distinct domains: The 25 kD N–terminal domain (NTD), the 35 kD 
middle domain (MD) and the 12 kD C–terminal domain (CTD) (Pearl and Prodromou, 2006). 
The eukaryotic NTD is connected to the MD via a highly charged hinge region, which varies 
in length and composition between species and which is essential for yeast Hsp90 to function 
(Louvion et al., 1996). Hsp90 participates in general chaperoning activities to restore 
proteostasis under stressful conditions, in addition to client protein maturation. Chaperone 
activity has been described for the Hsp90 NTD and CTD, and they function independently of 
each other to recognize different subsets of substrate to dissociate their aggregation (Scheibel 
et al., 1998). 
In contrast, client protein folding requires extensive conformational changes of full length 
Hsp90 and a multitude of highly ordered processes of protein–protein interactions (Taipale et 
al., 2010). All three domains of Hsp90 have been found to interact with client proteins. Hsp90 
dimerizes via its CTDs to subsequently undergo conformational changes – it oscillates 
between open and closed conformations. The state that Hsp90 adopts is ultimately dictated 
through the binding of cochaperones, which also direct client binding and ATP hydrolysis via 
the N–terminal ATPase for the maturation of client proteins. The entire process is called the 
catalytic cycle (Röhl et al., 2013). 
 
HSP90 CLIENT PROTEINS 
In all eukaryotes tested, Hsp90 is essential, abundantly expressed and highly inducible by 
stress. Most proteins do not require Hsp90 for folding in vivo. However, more than 300 Hsp90 
client proteins are known. They are members of multiple protein families and do not seem to 
display a common structural feature characterizing them as Hsp90 client proteins (for a 
regularly updated list of Hsp90 client proteins, refer to www.picard.ch/downloads). An 
approach to unravel the determinants of client protein recognition by Hsp90 showed that the 
weak client protein endothelial growth factor receptor (EGFR = ErbB1) can be converted into 
a strong client protein by mutation of a short stretch of amino acid residues in a putative 
Hsp90 interaction site (Xu et al., 2005). The mutated sequence in EGFR was identical to that 
in wildtype ErbB2, a bona fide Hsp90 client protein which strongly depends on chaperone 
function. The dichotomous expression ‘weak’ client and ‘strong’ client was originally coined 
following the observation that certain client proteins are rapidly degraded when Hsp90 was 
pharmacologically inhibited, while others remained comparably stable. In contrast to this 
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convenient example, however, sequence alignments of all known Hsp90 client proteins 
revealed that the amino acid sequence cannot be the sole factor to determine the dependence 
of these proteins on Hsp90. Only a recent work has shed light on the principle of client 
protein recognition, and classification was extended to fit the observation that client proteins 
exist which display any degree of dependence on Hsp90 – with respect to its interaction, as 
well as the cellular fate of the client protein subsequent to dissociation from Hsp90 – between 
weak and strong (Taipale et al., 2012). While the process of maturation for the kinase class of 
Hsp90 client proteins requires the cochaperone Cdc37 (cell division cycle 37 homolog) (Pearl, 
2005), the process itself is still poorly understood. However, the intrinsic thermal stability of 
the functional kinase domain dictates the dependence of these proteins on Hsp90, rather than 
their amino acid sequence: There is a negative correlation between strong client proteins, and 
parameters such as solubility and the availability of solved crystal structures (Taipale et al., 
2012). Thus, client proteins can be characterized by binding pockets, catalytic or allosteric 
domains which are comprised of structural networks with low intrinsic stability – typically, 
the interaction of Hsp90 with the metastable client proteins is dynamic and keeps them poised 
for activation (Taipale et al., 2010). In addition to kinases, E3 ubiquitin ligases constitute a 
prominent class of Hsp90 client proteins (Taipale et al., 2012), but this interaction is the least 
researched. Furthermore, nuclear hormone receptors are a peculiar subclass of transcription 
factors that require Hsp90 for maturation (Pratt and Toft, 1997), of which the GR will be 
discussed in greater detail later. 
 
THE CATALYTIC CYCLE OF HSP90 AND THE ROLE OF COCHAPERONES 
The energy necessary for the catalytic cycle of Hsp90 is provided through binding of ATP to 
a pocket in the NTD of Hsp90, followed by closing of a lid–structure over the nucleotide. The 
MD subsequently interacts with the NTD – thereby closing the overall chaperone 
conformation – and participates in ATP hydrolysis, making Hsp90 a split ATPase (Shiau et 
al., 2006; Ali et al., 2006). Since ATP hydrolysis takes place only when the protomers are 
twisted around each other, being in contact both at the C–terminus and the NTD, there seems 
to exist a high degree of communication between the domains of Hsp90 as well as between 
the protomers. Cochaperones which bind to Hsp90 throughout the catalytic cycle in a 
sequential manner either enhance – or are permissive for – this communication, thereby 
influencing its progression and thus, client protein fate (Mayer, 2010; Röhl et al., 2013). 
Over 20 cochaperones of Hsp90 are known to date, and they can be divided into three distinct 
functional classes: (I) The client recruiter cochaperones Hop (Hsp90–organizing protein), 
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Cdc37, and Sgt1 (suppressor of G2 allele of Skp1) facilitate the loading of Hsp90 client 
proteins into the complex. All of these cochaperones favour the open conformation of Hsp90 
for client loading, and except for Sgt1, they reduce its ATPase activity (Southworth and 
Agard, 2011; Roe et al., 2004; Kadota et al., 2010). (II) A cochaperone which remodels 
Hsp90 conformation is Aha1 (activator of heat shock protein 90 ATPase 1). Binding of one 
Aha1 to an Hsp90 dimer accelerates the closed and catalytically active state (Retzlaff et al., 
2010; Li et al., 2013). The autoinhibition of the phosphatase activity of Pp5 (protein 
phosphatase 5) is relieved upon binding to Hsp90 to facilitate dephosphorylation of the 
chaperone, which influences its function (Wandinger et al., 2006; Vaughan et al., 2008). (III) 
The late–acting cochaperone p23 (Sba1; increased sensitivity to benzoquinone ansamycins 1) 
significantly reduces Hsp90 ATPase activity by trapping the chaperone in the completely 
closed conformation, with client protein loaded to facilitate maturation (McLaughlin et al., 
2006). Upon binding of CHIP (carboxyl terminus of Hsp70 interacting protein) to Hsp90, 
Hop and p23 are displaced from the chaperone, and the ubiquitin ligase domain of CHIP 
directs the client proteins for proteasomal degradation (Connell et al., 2001). 
About 75% of the cochaperones contain a TPR–motif (tetratricopeptide–motif) to interact 
with the MEEVD–motif at the very end of the carboxyterminus of Hsp90, while others 
interact with distinct domains of Hsp90. Thus, at least some cochaperones share the same 
binding site within Hsp90. Considering that Hsp90 is 10–1000 times more abundant than any 
cochaperone, the existence of mixed and asymmetric complexes in vivo is likely (Röhl et al., 
2013). Depending on the cellular environment, such as cochaperone expression and client 
protein abundance, certain types of complexes may dominate inside different cell types or 
under pathologic conditions. 
 
Through attempts to describe the influence of cochaperones on the full catalytic cycle, a 
picture has emerged through careful assembly of insights gained by the utilisation of a vast 
array of biochemical and structural biology techniques. All information was gained with 
purified proteins, and nuclear hormone receptors were the client proteins used in these highly 
artificial models – other classes of Hsp90 client proteins may require different mechanisms. 
Current knowledge suggests that the two TPR–domains in Hop bind to the MEEVD–domain 
of both Hsp70 – a promiscuous chaperone which is required for specific and 
folding/unfolding steps of nuclear hormone receptors at multiple levels (Pratt et al., 2006; 
Kirschke et al., 2014) – and Hsp90 to facilitate client protein loading. The second MEEVD of 
the Hsp90 dimer then binds a TPR–motif containing PPIase (peptidylprolylisomerase). The 
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activator Aha1 binds upon release of Hop and Hsp70. Then, p23 displaces Aha1 and the 
nucleotide is trapped in the closed chaperone conformation to be hydrolyzed. Only after 
ATP–hydrolysis, the client and cochaperones are released (Scheufler et al., 2000; Retzlaff et 
al., 2010; Li et al., 2011). Intriguingly, very recently it has been shown that hydrolysis of ATP 
by Hsp90 was required for the release of GR from Hsp70, and that the chaperoning activity of 
Hsp90 on GR did not require ATP hydrolysis (Kirschke et al., 2014). In sum, the scheme 
might not be complete and function in a more complex manner in vivo. For example, it was to 
date not possible to integrate Hsp70/Hop into the catalytic cycle of kinases, since most 
kinases directly interact with Cdc37 and this interaction is abolished upon inhibition of Hsp90 
(Taipale et al., 2012). On the other hand, Hsp70 inhibitors lead to the degradation of Hsp90 
client proteins (Taldone et al., 2014; Wang et al., 2010; Powers et al., 2008). 
 
A further layer of control of chaperone cycle progression and function to adapt to differential 
cellular needs is through post–translational modifications (Mollapour and Neckers, 2012). 
Modifications within the different domains were shown to affect global aspects of Hsp90 
function: Phosphorylation, sumoylation, and S–nitrosylation influenced Hsp90 ATPase 
activity, cochaperone binding, dimerization and conformational equilibrium, thereby either 
constituting switch points for the communication between the domains or modulating the 
function of the modified domains (Soroka et al., 2012; Retzlaff et al., 2009; Martinez–Ruiz et 
al., 2005; Mollapour et al., 2010; Beebe et al., 2013; Mollapour et al., 2014). As will be 
introduced later, it was tempting to assume that small molecule inhibitors which bind to the 
different domains of Hsp90 might thus elicit distinct effects on chaperone function. 
 
HSP90 IN CANCER 
Hsp90 is overexpressed in many solid tumors and haematological malignancies (Isaacs et al., 
2003; McDowell et al., 2009). It serves to buffer intracellular stress caused by the 
transformation and oncogenicity, and it promotes the functional state of oncogenic client 
proteins which are amplified, mutated, or mislocated (Trepel et al., 2010). Hsp90 in cancer 
cells exists in a hyperactive complex as compared to that found in normal cells, i.e. the 
ATPase activity of cancer cell Hsp90 is greatly enhanced (Kamal et al., 2003). It is assumed 
that the composition of cancer cell Hsp90 complexes as well as post–translational 
modifications of Hsp90 are the cause for the observed hyperactivity. This furthermore implies 
that malignant cells display increased dependence on Hsp90, which is reflected by the fact 
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that mutant oncoproteins are particularly unstable and consequently require strongly increased 
chaperoning activity (Whitesell and Lindquist, 2005). 
Many of the known client proteins constitute central hubs of pathways that govern the five 
hallmarks of cancer (Whitesell and Lindquist, 2005). Malignant cells need to proliferate, and 
they require unlimited replicative potential to do so. Cancer cells must be able to trigger 
survival pathways, withstand stress (such as nutrient deprivation or hypoxia), and they need to 
induce vascularisation for further growth. At the final stage, cancer cells must evade 
restraining tissue architecture to be able to metastasize (Fig. II). 
Therefore, pharmacologic inhibition of Hsp90 simultaneoulsy impedes multiple oncogenic 
pathways, depriving cancer of its hallmark characteristics. Two distinct classes of Hsp90 
inhibitors to combat cancer will be introduced in the following paragraphs: N–terminal and 
C–terminal Hsp90 inhibitors. 
 
 
Figure II – The hyperactive Hsp90 complex in cancer cells promotes tumorigenesis through 
activation of oncogenic client proteins. Hsp90 client proteins encounter the chaperone in their native 
conformation. The catalytic cycle facilitates conformational changes in the clients which poise them 
for activation, thus driving tumorigenesis. Prominent oncogenic client proteins include: The steroid 
hormone receptors estrogen receptor (ER), androgen receptor (AR) and GR (Bagatell et al., 2001; 
Vanaja et al., 2002; Segnitz and Gehring, 1997); Cell division cycle 2 homolog (Cdc2), human 
epidermal growth factor receptor (ErbB2) and protein kinase B (Akt) (Garcia-Morales et al., 2007; 
Mimnaugh et al., 1996; Basso et al., 2002); The heat shock factors (HSF) and hypoxia inducible 
factors (HIF) (Zou et al., 1998; Minet et al., 1999); Matrix metalloproteinases (MMP) (Eustace and 
Jay, 2004)) and telomerase (TERT) (Holt et al., 1999). Pharmacologic inhibition of Hsp90 leads to 
client protein degradation in cancer cells. 
 
N–TERMINAL HSP90 INHIBITORS 
The structurally unrelated natural products Geldanamycin (Streptomyces hygroscopicus) and 
Radicicol (Diheterospora chlamydosporia) were shown to bind to the N–terminal ATPase 
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domain of Hsp90, thereby depriving the catalytic cycle of ATP (Trepel et al., 2010). In the 
presence of N–terminal Hsp90 inhibitors most, if not all, proteins which require Hsp90 for 
proper folding consequently lose activity, aggregate, and are targeted for ubiquitination and 
subsequent degradation through the proteasome. It quickly became clear that these molecules 
are potent anticancer agents, and that their antitumorigenic activity is based on the targeted 
degradation of numerous oncogenic client proteins (Xu and Neckers, 2007). 
The nucleotide binding site in the N–terminus of Hsp90 is special because ATP is bound in a 
kinked conformation. The so–called Bergerat ATP binding–fold is unique to a superfamily of 
ATPases also including DNA gyrase and the mismatch repair protein MutL (GHL–family) 
(Dutta and Inouye, 2000). With Hsp90 being the only eukaryotic protein of this superfamily 
(Roe et al., 1999), N–terminal Hsp90 inhibitors bind the chaperone with astonishing affinity 
and specificity. In addition, the previously mentioned, hyperactive species of Hsp90 detected 
in cancer cells exhibits strongly increased affinity towards these compounds as compared to 
the affinity of Hsp90 in normal cells – this class of inhibitors preferentially lead to cancer cell 
death (Kamal et al., 2003; Moulick et al., 2011; Mollapour et al., 2014). The tumor selectivity 
achieved with N–terminal Hsp90 inhibitors gained tremendous attention from the 
pharmaceutical industry: Nine structurally unrelated compounds which target the ATPase 
domain are currently in clinical development to combat cancer, with positive outcomes 
(www.clinicaltrials.gov). 
 
C–TERMINAL HSP90 INHIBITORS 
The necessity to develop an additional class of Hsp90 inhibitors can be explained by the fact 
that several N–terminal Hsp90 inhibitors exhibit severe side effects such as liver, intestinal, 
pulmonary, and ocular toxicity. The clinical development of many of them was discontinued. 
At the cellular level, N–terminal Hsp90 inhibitors elicit the heat shock response, which 
includes the upregulation of anti–apoptotic genes such as Hsp70 (Zou et al., 1998; Richter et 
al., 2010). The induction of Hsp70 promotes the chemoresistance of cancer cells and 
desensitizes for Hsp90 inhibition itself (Gabai et al., 2005; Chatterjee et al., 2012; Powers et 
al., 2008; Zaarur et al., 2006). Thus, these drugs trigger a negative feedback loop which 
induces resistance towards their own mechanism of action: Higher doses are necessary, which 
in turn are expected to show more severe side effects. 
The natural antibiotic Novobiocin (Streptomyces niveus) was thought to be an additional 
inhibitor of the N–terminal ATPase domain of Hsp90, since it inhibits DNA gyrase (Ali et al., 
1993). Surprisingly, affinity purification experiments, analyses with trypsin digestion patterns, 
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and molecular modelling have shown that Novobiocin binds to a cryptic nucleotide binding 
pocket in the C–terminal domain of Hsp90, and that cancer cells undergo apoptosis due to the 
degradation of oncogenic client kinases upon inhibition with this small molecule (Marcu et 
al., 2000a; Marcu et al., 2000b; Matts et al., 2011), without induction of the heat shock 
response (Donnelly and Blagg, 2008). This functional discrepancy was the first evidence that 
it is possible to modulate Hsp90 activity in specific ways using compounds that bind to 
different domains of the chaperone. Additional work revealed that after binding, Novobiocin 
forces Hsp90 into a conformation that promotes the release of, for example, the client heme–
regulated eIF2α kinase before it completes maturation (Yun et al., 2004). The composition of 
cochaperone–Hsp90 complexes in the presence of C–terminal Hsp90 inhibitors differs greatly 
from that observed after binding of N–terminal Hsp90 inhibitors (Söti et al., 2002; Allan et 
al., 2006; Smith et al., 1995; Thulasiraman and Matts, 1996). Furthermore, the recent finding 
from Kirschke et al. that the activation of GR which was partially unfolded by Hsp70 requires 
the CTD of Hsp90 independent of ATP–hydrolysis (Kirschke et al., 2014) strongly suggests 
that C–terminal Hsp90 inhibitors could modify the chaperoning activity in a distinct fashion 
compared to N–terminal Hsp90 inhibitors: With respect to GR, the hydrolysis of ATP by the 
N–terminal Hsp90 ATPase is uncoupled from the chaperoning activity mediated by the C–
terminal domain. Yet, also for this mechanism, ATP–hydrolysis by Hsp90 is essential for the 
activation of GR, namely to release it from Hsp70 for subsequent maturation. 
Silibinin, the major constituent and active ingredient of extracts of milk thistle (Silybum 
marianum) seeds, was also shown to be an Hsp90 inhibitor, and its effects recalled those 
elicited by C–terminal Hsp90 inhibitors (Zhao et al., 2011). 
 
THE GLUCOCORTICOID RECEPTOR 
GR is a nuclear hormone receptor encoded by the NR3C1 gene. Transcription of this gene is 
translated into three GR isoforms, of which only the alpha isoform can bind Gcs. Alternative 
splicing results in a unique 15 amino acid stretch within the carboxy–terminus of GRβ, the 
presence of which disturbs the allosteric network of the ligand binding pocket of the receptor, 
thus rendering it unable to bind Gcs. This isoform is expressed in certain tissues, can exert 
dominant negative effects on GRα in experimental settings, but its role in vivo is under debate 
(Bamberger et al., 1995; Vottero and Chrousos, 1999; Carlstedt–Duke, 1999). Of relevance 
for this work, GRβ was found to be equally expressed in corticotroph adenomas as compared 
to normal pituitary (Dahia et al., 1997) and likely does not play a role in the pathogenic 
mechanism of Cushing’s disease. The P–isoform is truncated at the carboxy terminus (Krett et 
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al., 1995). It has been detected in some types of Gc–resistant tumors and haematological 
malignancies, but was shown to enhance GRα activity in experimental settings (Parks et al., 
1998; Moalli et al., 1993; de Lange et al., 2001). No reports exist on the expression of GR–P 
in corticotroph adenomas. Since only the isoform capable of binding Gcs was investigated 
here, the designation GR stands henceforth for GRα. 
As a typical nuclear receptor, GR consists of a ligand binding domain (LBD), a DNA binding 
domain, and activator function domains. In addition to fulfilling the action that gave the 
domains their name, they can and do interact with other proteins, including other GR 
monomers for dimerization (Nicolaides et al., 2010). Unliganded GR (apo–GR) is mainly 
localized in the cytoplasm. Upon binding to its ligand (holo–GR), the receptor rapidly 
translocates into the nucleus to modulate target gene activity. Two mechanistically different 
actions are exerted by the activated GR: Trans–activation and trans–repression (Nicolaides et 
al., 2010). In trans–activation, a homodimer of GR directly binds to GR response elements 
(GREs) in the promoter region of target genes to interact with members of the nuclear 
receptor coactivator families such as NCoA–1 (SRC–1), NCoA–2 (TIF2, GRIP1), and the 
cointegrator p300/CBP. The transcription of target genes is induced and/or enhanced through 
the subsequent relaxation of the chromatin structure, as well as augmentation of promoter 
clearance and recruitment of RNA polymerase II (Voegel et al., 1996; Onate et al., 1995; 
Chakravarti et al., 1996; McKenna and O'Malley, 2002). Important insights into the 
mechanistic aspects of transcriptional control conferred by GR have been made with 
constructs containing the mouse mammary tumor virus long terminal repeat (Cordingley et 
al., 1987), which was also used in the present work to detect GR trans–activation. 
In trans–repression, the GR antagonizes the activating function of a subset of transcription 
factors including Nur77, NFKB, and AP1 (Adcock et al., 1999; Konig et al., 1992; Philips et 
al., 1997b; Heck et al., 1994). This mechanism does not involve the binding of dimeric GR to 
DNA but binding to the activated transcription factors on their respective response elements 
as a monomer, which induces a distinct conformation of GR to allow for recruitment of 
histone deacetylases (HDACs) and other corepressors to shut down target gene transcription 
via chromatin remodelling and/or inhibition of RNA polymerase II promoter clearance (Ito et 
al., 2000; Bilodeau et al., 2006; Nissen and Yamamoto, 2000; De Bosscher et al., 2003). The 
anti–inflammatory actions of GR are mediated mainly through trans–repression (Hayashi et 
al., 2004). The negative feedback mechanism of Gcs on the HPA axis at the hypophyseal 
level (normal corticotroph cells) acts through this mechanism as well (Philips et al., 1997b; 
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Bilodeau et al., 2006) and was investigated in the work presented here, since corticotroph 
adenoma cells are resistant to Gc–feedback. 
 
THE ROLE OF HSP90 IN GLUCOCORTICOID RECEPTOR FUNCTION 
In order to fulfil its activity as a transcription factor, GR requires multifaceted interaction with 
Hsp90 both before and after binding to Gcs. As an overview depicted in Figure III, Hsp90 
facilitates receptor maturation into its high–affinity binding state for steroid, mediates the 
rapid translocation of activated GR into the nucleus, and impacts transcriptional complexes on 
the target genes which contain GR (Fig. III). 
 
 
Figure III – Rationale of Hsp90 in GR function. (1) Physiological levels of Hsp90 are essential for 
the maturation of the GR–LBD into its high affinity steroid binding conformation. Through continuous 
interaction, the chaperone sequesters GR in the cytoplasm until the binding of agonist triggers a 
cascade of events, including the Hsp90–dependent transport into the nucleus, where the chaperone is 
replaced by transcriptional cofactors. In experimental settings, both reduced (2) and strongly elevated 
expression levels (3) of Hsp90 impede GR signalling at different steps. 
 
The quest for the molecular target of Gcs started at the biochemical level. A heteromeric 
protein complex that bound this steroid was identified using sucrose gradient centrifugation of 
cellular lysate (Baxter and Tomkins, 1971). The complex was dynamic, and it consisted of 
three proteins of which only one was found to actually bind steroid (Yamamoto et al., 1974; 
Housley et al., 1985). The other two proteins were a dimer of Hsp90 (Joab et al., 1984). An 
inhibitory role in GR signalling was initially attributed to Hsp90 due to the observations that 
cellular lysate containing GR bound to Hsp90 could not bind to DNA. Following artificial 
dissociation from Hsp90 in cellular extracts through elevated temperature, ionic strength, pH, 
or dilution, GR did bind to DNA (Harmon et al., 1988; Nielsen et al., 1977). However, GR 
which was dissociated from Hsp90 under such conditions did not bind Gcs in the first place 
(Bresnick et al., 1989). Since Gcs regulate a plethora of processes, the ability of GR to sense 
physiological Gc–levels in order to shape the cellular responses was considered the logic basis 
for its function. Furthermore, Gc–binding is necessary for GR to bind to specific response 
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elements in DNA in cells (Becker et al., 1986). Later, a system in which the interaction 
between Hsp90 and GR inside a living cell could be investigated more in detail was wanted. 
A yeast strain was created, in which the protein level of Hsp90 was reduced to 5% of that of 
the WT strain (Picard et al., 1990). While yeast cells do not have endogenous steroid hormone 
receptors, mammalian steroid hormone receptors are functional when overexpressed (Schena 
and Yamamoto, 1988). The strongly reduced expression of Hsp90 rendered GR free from 
Hsp90 – but merely being dissociated from Hsp90 in the absence of hormone did not confer 
activation on GR function in the cellular setting. While GR was not targeted for degradation 
in the mutant strain, only more than 20–fold higher concentrations of agonist activated GR in 
the mutant compared to GR expressed in the WT strain (Picard et al., 1990). In a different 
approach, a temperature sensitive Hsp90 mutant displayed WT activity at ambient growth 
temperature in yeast with respect to chaperoning activity of GR. At elevated temperature 
however, this mutant lost chaperoning activity, and hence GR did not function (Nathan and 
Lindquist, 1995). It was suggested that GR requires continuous interaction with Hsp90 to 
maintain its high–affinity conformation to bind Gcs, and that binding of Gcs to GR must 
constitute a dominant conformational switch that acts on the entire receptor. 
In the following years, different experimental approaches succeeded in showing that ATP 
together with purified Hsp40, Hsp70, Hop and Hsp90 could reassemble a complex to refold 
salt–stripped (native) GR into its high–affinity binding state (Dittmar and Pratt, 1997). GR 
thus reconstituted quickly lost its high–affinity conformation at elevated temperature, and p23 
was shown to stabilize the high–affinity state through the creation of a stable apo–GR::Hsp90 
complex, which kept GR in a conformation able to bind agonist (Dittmar et al., 1997). Rabbit 
reticulocyte lysate (RRL), which abundantly contains the Hsp90 cochaperone complex, could 
also mature GR when an ATP–regenerating system was included (Dittmar et al., 1996). RRL 
contains cochaperones in addition to the purified protein assembly system (Hsp40 – Hsp70 – 
Hop – Hsp90 – p23). Proteins such as Aha1, immunophilins, and protein phosphatases greatly 
influence client protein maturation, and this system is more reminiscent of intracellular 
folding processes than the purified protein assembly system (Pratt et al., 2006). 
Common knowledge dictated that binding of Gcs to GR causes dissociation of the receptor 
from Hsp90 (Pratt and Toft, 1997). Due to technical limitations, it was not possible to detect 
the dynamic interactions between holo–GR and Hsp90 after the agonist elicited the 
conformational change in the receptor which allowed for translocation and cofactor 
recruitment. An elegant work by Czar et al. demonstrated that Hsp90 is required for the rapid 
translocation of holo–GR into the nucleus in order to act as a transcription factor (Czar et al., 
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1997). It has been shown that the N–terminal Hsp90–inhibitor Geldanamycin quickly 
abolished the agonist binding activity of GR, which was followed by proteasomal degradation 
of the receptor after prolonged exposure to the inhibitor (Whitesell and Cook, 1996; Segnitz 
and Gehring, 1997). To circumvent the influence of Geldanamycin on GR prior to agonist 
binding, cells were incubated with Dexamethasone at low temperature to allow for binding to 
GR. Subsequently, Geldanamycin was added before the cells were exposed to growth 
temperature. The receptor did not translocate to the nucleus in an active process, only by 
slow, passive diffusion (Czar et al., 1997). It was thus shown that GR continues to require 
Hsp90 for certain functions also after the structural changes induced by the binding of agonist. 
It was later shown that holo–GR indeed interacts with Hsp90 (Lorenz et al., 2014; Fang et al., 
2006; Kirschke et al., 2014). 
Long after it was known that Hsp90 interacts with the LBD of GR (Gehring and Arndt, 1985; 
Xu et al., 1998; Howard et al., 1990), Fang et al. provided insights into how the dynamic 
interactions of holo–GR with Hsp90 occur (Fang et al., 2006). The LBD of GR consists of an 
allosteric network that transmits hormone–induced conformational changes inside the ligand 
binding pocket to a hydrophobic groove on its surface. This groove interacts with conserved 
LxxLL–motifs in amphipathic α–helices of coregulators, Hsp90, and GR itself when bound to 
agonists (Bledsoe et al., 2002; Kauppi et al., 2003; Fang et al., 2006). It was demonstrated that 
apo–GR interacts with the helix motif 10 of Hsp90 (Hsp90–HM10), which forces the flexible 
helix 12 of GR (GR–H12) to occupy the hydrophobic groove to stabilize it. Since 
communication between the ligand binding pocket and the hydrophobic groove is 
bidirectional, a stable groove likewise stabilizes the ligand binding pocket, thus preventing it 
from collapsing – the high affinity conformation of GR towards its agonist is preserved. Upon 
binding of agonist, the flexible GR–H12 displaces Hsp90–HM10 and allows the hydrophobic 
groove of holo–GR to interact with Hsp90 via its helix motif 9 (Hsp90–HM9), again to 
protect against collapse (Fang et al., 2006). 
To further understand the role that Hsp90 plays in modulating the highly dynamic allosteric 
system of the GR–LBD, a comprehensive screen for GR mutants which increase hormone 
responsiveness was conducted in yeast (Ricketson et al., 2007). Single point mutations that 
increased GR activity were identified, and these mutations were located inside the above 
mentioned allosteric network. In contrast to the increased transcriptional activity observed in 
yeast however, these mutants almost exclusively displayed impaired GR signalling in 
mammalian cells. This finding likely reflects the flexible effects of GR in high eukaryotes 
such as trans–activation, trans–repression, and mixed agonist/antagonist activities of RU–
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38486, whereas this ligand is a pure antagonist in yeast. In any case, the point mutations 
conferred stable structural changes in the GR–LBD independent of Hsp90: When the mutants 
were expressed in bacteria, which lack the chaperone machinery to mature nuclear receptors 
(with the exception of the Hsp90 homolog HtpG), they displayed increased agonist binding 
capacity as compared to WT–GR (Ricketson et al., 2007). It can be argued that the stable 
changes induced by the mutations on the allosteric network annihilate the structural flexibility 
conferred on WT–GR through Hsp90 and cofactors to function in a cell type specific manner. 
These findings demonstrated multifacetted roles of Hsp90 in the function of GR. 
 
Artificial overexpression of Hsp90 has a negative impact on GR signalling in experimental 
settings (Kang et al., 1999; Freeman and Yamamoto, 2002). In contrast to low levels of 
Hsp90, where the partially denatured GR bound to Hsp70 cannot be matured into its high–
affinity binding conformation, the overexpression of Hsp90 interferes with later steps in GR 
activity. High nuclear Hsp90 levels impeded hormone responsiveness through the dissociation 
of holo–GR from its cognate response elements (Kang et al., 1999). Furthermore, if Hsp90 
was artificially targeted to the vicinity of a GRE–containing promoter, it displaced 
transcriptional cofactors from GR in transcriptional complexes, likewise leading to a 
reduction in GR activity (Freeman and Yamamoto, 2002). Since endogenous Hsp90 is 
recruited to GR–responsive genes (Freeman and Yamamoto, 2002), it is possible that the 
abnormally high expression levels of Hsp90 observed in cancer might impact holo–GR. 
In the work presented here, evidence is provided that strongly increased levels of Hsp90α in 
corticotroph adenoma cells negatively interfere with GR signalling in a step prior to the 
binding of hormone, and that C–terminal Hsp90 inhibitors reverse this inhibitory mechanism. 
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5 MATERIALS & METHODS 
 
5.1 REAGENTS 
Chemicals and Reagents Company 
17–AAG Tocris 
3
H–Dex Perkin Elmer 
ABC (Avidin Biotin Complex) Vector 
Acetic Acid Sigma 
Acridine orange Sigma 
Acrylamide/Bis–acrylamide 30% solution Sigma 
ACTH Bachem 
AG1–X8 BioRad 
Agar Life Technologies 
Agarose Roth 
Ampicillin Sigma 
APS Sigma 
AtT–20 clone D16v–F2 ATCC 
Β–Mercaptoethanol Merck 
Bradford Protein Assay BioRad 
BSA Invitrogen 
Charcoal Roth 
Chloramin T Merck 
Clarity ECL BioRad 
DAB Sigma 
DAPI Sigma 
Developer Solution Kodak 
Dextran T70 Roth 
DMEM Gibco 
DMSO Roth 
DTT Sigma 
Dynabeads Protein G Invitrogen 
EDTA Sigma 
Entellan Merck 
Ethidium Bromide Sigma 
EtOH 100% Roth 
FCS Gibco 
Fixer Solution Kodak 
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Chemicals and Reagents Company 
Forskolin Sigma 
Glucose Merck 
Glycerol Sigma 
HCl Roth 
HEPES Sigma 
Hydrogen Peroxide Solution 30% Sigma 
125
I PerkinElmer 
Igepal CA-630 Sigma 
IPTG Sigma 
Isopropanol Sigma 
L–Glutamine Biochrom 
Lipofectamine2000 Invitrogen 
Luciferin PJK 
MEM vitamins Biochrom 
Milk powder Roth 
Na2MoO4 Sigma 
NaCl Roth 
NaOH Roth 
Novobiocin Calbiochem 
ONPG Sigma 
Optimem Gibco 
Partricin Biochrom 
Passive Lysis Buffer Promega 
PEG 6000 Merck 
Peptone MP Biomedicals 
Penicillin + Streptomycin Mix Biochrom 
PFA Sigma 
Plasma ACTH Kit ImmuChem MP Biomedicals 
Plasma Corticosterone Kit DRG Instruments 
Plasmid Extraction Kit Qiagen 
Poly–L–Lysine Sigma 
Poly–L–Lysine Coated Slides Sigma 
Polystyrene Microtiter Plates Corning 
ProLong Antifade Gold Invitrogen 
Propidium Iodide Sigma 
Protease Inhibitor Cocktail Sigma 
Protein G Dynabeads Invitrogen 
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Chemicals and Reagents Company 
PVDF Membrane Millipore 
QuikChange II XL Mutagenesis Kit Agilent Technologies 
RNAse A Promega 
RU–38486 Tocris 
Sample Buffer (4x) Roth 
Scintillation Vials Roth 
SDS Roth 
Silibinin Sigma 
Silicur Hexal 
Sodium Bicarbonate Sigma 
Sodium Carbonate Sigma 
Sodium Disulfite Merck 
Sodium Hydroxide Sigma 
Sodium Molybdate Sigma 
Substrate Reagent for HRP R&D 
Sulfuric Acid Sigma 
TEMED Sigma 
Toluidine Blue Sigma 
Tris Base Roth 
Triton X–100 Roth 
Trypsin/EDTA Biochrom 
Tween–20 Sigma 
Ultima Gold Scintillation Fluid Perkin Elmer 
WST–1 Assay Roche 
Xylol Roth 
Yeast extract MP Biochemicals 
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5.2 SOLUTIONS 
Buffer Composition 
BCB Na2CO3 : 3.03 g l
–1
 
  NaHCO3 6 g l
–1
 
  adjust to pH 9.5 
Charcoal/Dextran Suspension Charcoal : 100 g l
–1
 
  Dextran T70 : 10 g l
–1
 
  in 10 mM Tris buffer pH 7.8 
HDB buffer Glucose : 10 mM 
NaCl : 137 mM 
KCl : 5 mM 
Na2HPO4 : 0.7 mM 
HEPES : 25 mM 
adjust to pH 7.3 
Partricin : 500 µg l–1 
Penicillin/Streptomycin : 10
5
 U l
–1
 
LB medium Peptone : 10 g l
–1
 
Yeast extract : 5 g l
–1
 
NaCl : 5 g l
–1
 
NaOH 1M : 2 ml l
–1
 
adjust to pH 7.0    
Lower Tris Buffer  Tris : 182 g l
–1
 
SDS : 4 g l
–1
 
adjust to pH 8.8 
ONPG buffer 2x Na2HPO4 1M : 55.3 ml 
NaH2PO4 1M : 29.3 ml 
DDW : 339.2 ml 
MgCl2 * 6H2O : 154.5 mg 
ONPG : 500.0 mg 
b-Mercaptoethanol  14M : 2.5 ml 
freeze aliquots at -20 °C 
PBS NaCl : 8 g l
–1
 
  KCl : 0.2 g l
–1
 
  Na2HPO4.2H2O : 1.44 g l
–1
 
  KH2PO4 : 0.2 g l
–1
 
  adjust to pH 7.4  
PEG buffer Polyethylenglycol 6000 : 60 g l
–1
 in phosphate 
buffer 
PFA 4% in PBS Paraformaldehyde : 40 g l
–1
 in PBS or TBS 
  freeze aliquots at –20 °C 
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Buffer Composition 
Phosphate Buffer Na2HPO4 * 2 H2O : 7.06 g l
–1
 
  NaH2PO4 * 2 H2O : 1.32 g l
–1
 
  adjust pH to 7.3 
RIPA cell lysis buffer Tris HCl pH 8 : 50 mM 
NaCl : 150 mM 
NP–40 :1% 
Sodium Deoxycholate : 0.5% 
SDS : 0.1% 
Running Buffer Tris : 3.03 g l
–1
 
Glycine : 14.42 g l
–1
 
SDS : 1.00 g l
–1
 
adjust to pH 8.3 
Running Gel 10% (SDS-PAGE) DDW  : 6.6 ml 
Acrylamide : 8 ml 
Lower Tris-Base pH 8.8 :5 ml 
Ammonium persulfat 10% : 0.2 ml 
Temed : 0.008 ml 
Stacking Gel 4% (SDS-PAGE) DDW : 4.1 ml 
  Acrylamide :1 ml 
  Upper Tris Buffer  pH 6.8 : 0.75 ml 
  Ammonium Persulfat 10% : 0.06 ml 
  Temed : 0.006 ml 
TEDGM buffer Tris : 10 mM 
  NaCl : 50 mM 
  EDTA : 4 mM 
  Na2MoO4 : 10 mM 
  glycerol : 10% 
  DTT : 1 mM, add freshly prior to use 
Towbin Transfer Buffer Tris : 3.03g l
–1
 
Gycine : 14.42 g l
–1
 
Methanol : 150 ml l
–1
 
TBS Tris : 2.42 g l
–1
 
NaCl : 8 g l
–1
 
adjust to pH 7.6    
TBST Tris : 2.42 g l
–1
 
NaCl : 8 g l
–1
 
Tween 20 : 1 ml l
–1
 
Upper Tris Buffer Tris : 60.5 g l
–1
 
SDS : 4.0 g l
–1
 
  adjust to pH 6.6 
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5.3 ANTIBODIES 
Target Name Company Application Conjugation 
GR H–300 Santa Cruz IP, ICC - 
GR M–20 Santa Cruz IB - 
Hsp90α EPR3953 Epitomics IHC - 
Hsp90α/β H90–10 Thermo Scientific IB, ICC - 
Hsp90α ADI–SPA 771 Thermo Scientific IB, IP - 
Hsp90α/β clone 68/Hsp90 BD Biosciences ELISA - 
Cdk1 clone 1/Cdk1/Cdc2 BD Biosciences IB - 
β–actin 8H10D10 Cell Signaling IB - 
ACTH   MPI of Psychiatry RIA - 
non–immune Sc–2027 Santa Cruz IP - 
mouse–IgG 7076S Cell Signaling IB HRP 
rabbit–IgG 7074S Cell Signaling IB HRP 
rabbit–IgG BA1000 Vector IHC biotinylated 
rabbit–IgG A–11012 Life Technologies ICC AlexaFluor 594 
mouse–IgG A–11001 Life Technologies ICC AlexaFluor 488 
rabbit–IgG AP132 Millipore RIA - 
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5.4 METHODOLOGY 
 
IMMUNOHISTOCHEMISTRY 
In order to investigate the expression and subcellular localization of Hsp90α in human 
corticotroph adenomas as compared to normal human pituitary tissue, immunohistochemistry 
was conducted. 8 µm sections of frozen normal and adenoma tissue were cut in a cryostat 
(Leica CM3050 S) and bedded on poly–L–lysine coated glass slides. The tissue was fixed in 
freshly prepared cold PBS with 4% PFA, dehydrated and stored at 4°C until use. For the 
experiments, the sections were incubated for 5 min in TBS, followed by 30 min blocking in 
TBS with 10% goat serum. Endogenous peroxidase activity was blocked by 15 min 
incubation with TBS and 1% H2O2, and sections were incubated with antibody to Hsp90α 
(EPR3953 1:200 – Epitomics) diluted in TBS and 3% BSA ON at 4°C. After 3 washes in 
TBS, the biotinylated secondary antibody (BA1000 1:500 – Vector) was diluted in blocking 
solution and incubated for 30 min at RT. After 3 washes in TBS, the slides were incubated for 
30 min with the ABC complex. The ABC complex binds to the biotinylated secondary 
antibody, and since there are multiple biotin motifs on each antibody, the ABC complex 
which contains HRP enhances the signal in comparison to regular HRP–conjugated 
antibodies. The ABC complex was prepared 30 min prior to use in Tris–buffer to allow 
complex formation. After 3 washes in TBS, the slides were immersed in freshly prepared 
DAB (1 mg ml
–1
 in DDW) supplemented with 0.01% H2O2 until the signal was visible by eye. 
For each section stained for Hsp90α, the adjacent section was incubated in parallel without 
primary antibody to control for background. Only those sections which did not give a signal 
for the control were considered for analysis. After thorough washes in TBS, the slides were 
counterstained with toluidine blue (1 mg ml
–1
 in DDW), which stains the nuclei pale blue to 
allow for sighting of tissue organization. Excess color was removed by immersing the cells in 
70% ethanol supplemented with acetic acid, followed by dehydration and fixation in xylol. 
Slides were coverslipped in Entellan (VWR), and evaluated using the Zeiss Axioskop II. 
 
CELL CULTURE 
The murine corticotroph tumor cell line AtT–20 is a well characterized bona fide model for 
corticotroph function. AtT–20 clone D16v–F2 cells were obtained from ATCC and grown for 
maintenance in what will be referred to as cell culture medium: DMEM (Gibco 41965) 
supplemented with 10% FCS (Gibco – 10270 heat–inactivated for 1 hour at 55°C), 2 mM L–
glutamine (Biochrom), 100 U ml
–1
 penicillin/streptomycin (Biochrom) and 0.5 µg ml
–1
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partricin (Biochrom) at 37°C in a humidified atmosphere with 95% air and 5% CO2. These 
cells do not grow to confluency, and were thus split 1:5 every four days when they reached 
approximately 70–80% confluency. Splitting was done through digestion of cells in PBS with 
0.05%/0.02% trypsin/EDTA (w/v). 
Serum used for cell culture contains steroid hormones. This can interfere with assays that 
determine steroid hormone receptor function, such as GR. FCS was stripped using the 
charcoal method, and cell culture medium was supplemented with stripped FCS where 
indicated. To produce stripped FCS, 25 g of the anion exchanger resin AG1–X8 was stirred 
ON with 500 ml FCS. After settling of the resin, supernatant was decanted and mixed with 10 
ml charcoal/dextran suspension and stirred again ON at 4°C. The suspension was spun down 
for 10 min at 1000g, and the supernatant was sterile filtered, followed by storage at –20°C 
until use. 
 
PRIMARY CULTURES OF HUMAN CORTICOTROPH ADENOMAS AND NORMAL RAT 
PITUITARY CELLS 
Corticotroph pituitary adenomas were obtained from patients with Cushing’s disease that 
underwent transphenoidal surgery. Adenomateous tissue was washed with HDB buffer and 
mechanistically dispersed into small fragments, followed by enzymatic dispersion for 45 min 
at 37°C in solution containing 4 g l
–1
 collagenase, 0.01 g l
–1
 DNAse II, 0.1 g l
–1
 soybean 
trypsin inhibitor and 1 g l
–1
 hyaluronidase II. Cell viability was determined by acridine 
orange/ethidium bromide staining, and only cultures with viability above 90% were 
considered and grown in DMEM (Gibco 95530) supplemented with 10% stripped FCS and 
antibiotics for 48 h prior to treatment in 96–well plates. Treatment was done in cell culture 
medium with 0.1% stripped FCS. All experiments with human material were performed after 
approval of the local ethics committee of the Ludwig Maximilian University of Munich – 
Germany, and informed written consent was received from each patient whose pituitary 
adenoma tissue was used in the study. 
Primary cultures of normal pituitary was produced from rats. The size and architecture of the 
rat pituitary allows for dissection of the anterior pituitary from the intermediate lobe, the latter 
of which contains cells that produce ACTH as well and which could interfere with the 
measurements aimed to investigate the function of anterior pituitary corticotroph cells. Male 
Sprague–Dawley rats (at 6–7 weeks of age) were allowed to acclimate for 4 days at the 
Institute’s animal facility before sedation with CO2, decapitation and dissection of the anterior 
pituitary. Enzymatic dispersion of isolated pituitary was done as described above for pituitary 
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adenomas, and cells were seeded at a densitiy of 2 x 10
4
 cells per well in 96–wells in cell 
culture medium containing 10% stripped FCS and vitamins for 48 h. Treatment was done in 
cell culture medium with 1% stripped FCS plus MEM vitamins. 
 
WST–1 CELL VIABILITY ASSAY 
To assess the viability of cells under different treatment conditions, the WST–1 assay was 
used. This ready to use assay mixture contains tetrazolium salt, which is cleaved to soluble 
formazan in a cellular process which depends on the glycolytic production of NAD(P)H in 
mitochondria of cells, and the amount of formazan dye formed directly correlates with 
metabolically active (= viable) cells in the culture. 
AtT–20 cells in cell culture medium were seeded at 2 x 10
3
 cell per well in 96–well plates and 
left to attach for 24 h. Medium was changed to cell culture medium with 2% FCS and drugs 
were added for 96 h at the indicated concentrations with a constant DMSO concentration of 
0.2%. After drug incubation the medium was quickly replaced by DMEM with WST–1 
substrate according to the manufacturer’s instructions. After 30 min, the absorption was 
measured at 450 nm in a plate reader. Graphs were done using SigmaPlot v12.5. 
 
FACS ANALYSIS 
FACS was conducted to specifiy the effects of the small molecule inhibitors on the cell cycle. 
Fixation of cells with EtOH and staining with the fluorescent dye propidium iodide is a 
reliable and efficient method to determine the DNA content of cell populations. Propidium 
iodide intercalates with DNA in the nucleus of each cell. The cell sorter counts single cells in 
solution, forced in a stream through a thin capillary. Identification of single cells is made 
possible through a transparent section inside the capillary: the cell sorter sends light through 
that section when the cells are passed through at a constant pace and detects A) the forward 
scatter (FS) and the side scatter (SS), and subsequently B) a specific fluorescent signal. FS 
identifies the volume of a cell (important if, for example, plasma cell populations are 
investigated). SS identifies the quantitiy and characteristics of intracellular structures such as 
granularity, size of the nuclei etc. Figure M1a shows a SS/FS plot used in this work. Since the 
AtT–20 cell line was used, the readout depicts a homogenous cell population. The selection 
lines are set as a first threshhold for further analysis: unwanted artifacts such as debris (low 
signal) or very large aggregates (high signal) are thus excluded (Fig. M1a). Next, the 
fluorescent signal gained through propidium idodide excitation is processed. Figure M1b 
shows that the fluorescence signal gives 3 distinct outcomes for diploid cells (2n – G1 phase 
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of the cell cycle), tetraploid cells (4n – G2/M phase) and, for example, a doublet of two 
diploid cells sticking together (which is an artifact caused by cell preparation). The intensitiy 
of the fluorescent signal directly correlates with the DNA content of a cell (peak H), i.e. the 
peak for cells in S–phase lies between those obtained for 2n and 4n. The area under the curve 
(integral I) is the second parameter which allows to exclude doublets, since H = 1 for both a 
single diploid cell and for a doublet of two diploid cells (Fig. M1b). Counting doublets as one 
diploid cell would skew the result towards an underestimation of the relative amount of 
diploid cells. Figure M1c shows a plot which incorporates H over I, and a selection for 
apoptotic and single cells only (Fig. M1c). Figure M1d shows the cell cycle distribution: the 
number of events for each H are plotted, and cell cycle subpopulations are designated 
according to the DNA content of each event (subG1 – hypodiploid cells equal apoptotic cells). 
The graph calculates the percentage of 20.000 events which passed all gating criteria 
according to the thresholds (Fig. M1d). Using this process, the results in the work presented 
here were generated. Bar charts were done using Excel, and histograms with the EPICS 
System II Software. 
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Figure M1: Step by step schematic representation of FACS analyses conducted in the experiments of 
the present work. 
 
AtT–20 cells in cell culture medium were seeded at 3 x 10
5
 cells per well in 6–well plates and 
left to attach for 24 h. Medium was changed to cell culture medium with 2% FCS and the 
cells were incubated with the indicated drugs over time. DMSO was kept constant at 0.2% for 
all conditions. After incubation, cell supernatant was collected. The cells were washed in PBS 
and trypsinized in 1 ml per well for 4 min. The detached cell suspension was harvested into 8 
ml cell culture medium and pelleted at 600g together with the supernatant, followed by a 
wash in 10 ml cold PBS. The pellet was redissolved in 1 ml cold PBS and pure ethanol was 
added dropwise to a final concentration of 75% under slight vortexing. The cells were fixed 
for 24 h at –20°C, washed in 1 ml cold PBS and the pellet was redissolved in 500 µl PBS with 
10 µg ml
–1
 propidium iodide and 1 µg ml
–1
 RNAse A for 1 h at room temperature, followed 
by FACS in a Beckman–Coulter EPICS XL. 
 
IMMUNOBLOT 
The Western Blot is an invaluable molecular biological method which allows to determine the 
cellular content of specific proteins, and likewise, the influence of a vast number of conditions 
on these protein levels. Electrophoretic seperation according to the size of the proteins is 
followed by a transfer onto a sticky membrane which unspecifically binds protein. After 
blocking of the membrane at spots where no protein was transferred, specific antibodies are 
incubated which recognize the protein of interest. A secondary antibody coupled to HRP 
which recognizes the Fc–region of the primary antibody is incubated, and after washing, ECL 
substrate is added to the membrane, resulting in a light reaction. The light reaction is detected 
by a film, and the amount of protein correlates with the signal intensity, thus allowing for 
quantification. 
Total cellular protein, called the lysate, is mixed with sample buffer containing SDS and a 
reducing agent, mostly didthiothreitol (DTT) or β–mercaptoethanol. Cooking of the lysate 
with sample buffer leads to breakage of disulfide bonds in the peptide chain, destroying the 
secondary structure. The now linear polypeptide chain is equally covered by SDS, resulting in 
a net negative charge of the protein which correlates with its length. The mix is applied onto a 
polyacrylamide gel with varying pore sizes, depending on the percentage of acrylamide used 
for preparation. The stacking gel with the wells where the mix is filled into has a pH of 8.8. 
The running buffer contains glycine, which is zwitterionic at pH 8.8, building an ion–border 
towards the cathode. The proteins are sandwiched between glycine and the negatively charged 
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chloride of the running buffer on their way to the anode, resulting in concentrated thin layers 
of protein prior to their entering into the seperation gel. As soon as the proteins enter the 
seperation gel, which is at pH 6.8, the glycine is negatively charged and passes the proteins, 
thus allowing for seperation of proteins according to their size. After electrophoresis, the 
proteins are transferred onto a PVDF membrane in an electric field in transfer buffer 
according to Towbin, where specific proteins can be detected using antibodies. 
AtT–20 cells in cell culture medium were seeded at 3 x 10
5
 cells per well in 6–well plates and 
left to attach for 24 h. Medium was changed to cell culture medium with 2% FCS and the 
cells were incubated with the indicated drugs over time. DMSO was kept constant at 0.2% for 
all conditions. After incubation, the cells were washed in cold PBS, and scraped in 150 µl 
RIPA buffer per well with protease inhibitor cocktail. The crude lysate was frozen at –80°C 
until use. After rapid thawing in a 37°C waterbath, the crude lysate was passed 10x through 
an insulin needle, followed by 15 min centrifugation at 16.000g and 4°C. The supernatant was 
used and is referred to as lysate. The protein content of each lysate was determined using the 
Bradford method according to the manufacturer’s protocol. BSA was used as standard. The 
standard curve was determined for 25, 20, 10, 5 and 0 µg ml
–1
 of BSA. The Bradford reactive 
was diluted 1:1 in DDW and the samples were diluted as much as needed so that the values of 
the protein concentration were into the range of the standard curve. 100 µl of each standard 
and each sample were put in a transparent 96–well plate together with 50 µl of Bradford 
reactive. Absorbance was measured in a plate reader at 595 nm. Between 10 and 30 µg of 
total protein was mixed with 4x sample buffer (RotiLoad I) to a final concentration of 1x and 
boiled for 5 min at 95°C, followed by SDS-PAGE and transfer onto a PVDF membrane at 
constant 25V over night at 4°C in transfer buffer. The membrane was soaked in 100% 
methanol, air dried, followed by blocking in TBST with 5% skim milk for 1 hour at room 
temperature and incubation with primary antibody over night at 4°C, 3 x 5 min washing in 
TBST, and one hour incubation with secondary antibody at room temperature, 3 x washing 
for 5 min in TBST. Signal was obtained through incubation with ECL substrate and detection 
by a light sensitive film. 
 
HSP90–CTD BINDING ASSAY 
In order to investigate the binding site of Silibinin in Hsp90, a binding assay for small 
molecule compounds was developed. Morra et al. have demonstrated that chemical 
compounds can be immobilized to a polystyrene surface in the 96–well plate format, followed 
by incubation with the recombinant C–terminal domain of Hsp90 to allow for binding. The 
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bound protein was detected with antibodies, thus, this assay can principally be considered as a 
modified enzyme linked immunosorbent assay (Morra et al., 2010). 
The cloning of amino acids 566 to 732 of human Hsp90α (Hsp90–CTD) into pPROEXHTa 
was described previously (Young et al., 2003). The expression plasmid was a gift from Dr. 
Hartl (MPI of Biochemistry) to Dr. Hausch (MPI of Psychiatry). Expression in E. coli BL21 
was induced with IPTG (Sigma) and the His-tagged recombinant protein was purified using 
an Ni–NTA column (Quiagen), followed by dialysis into HG buffer to a final concentration of 
5 mg protein per ml. Aliquots of Hsp90–CTD were a gift from Dr. Hausch. 
To immobilize Silibinin to the polystyrene surface, it was dissolved in pH 9.5 bicarbonate 
buffer (BCB) with a final DMSO concentration of 5% and incubated ON at 4°C in untreated 
polystyrene microtiter plates (Costar 3695 – Corning). After a rapid wash in PBS, the wells 
were blocked in PBS with 1% gelatine for 1 h at RT. Recombinant human Hsp90–CTD was 
diluted in PBS with 1% BSA and incubated for 1 h at RT to allow for binding to immobilized 
Silibinin. After three washes in PBS, the wells were incubated for 1 h at RT with antibody 
directed against the C–terminus of Hsp90 (clone 68/Hsp90 1:1500 – BD Biosciences), diluted 
in PBS with 3% BSA and 0.1% Tween–20. After three washes in PBS, HRP–conjugated 
secondary antibody diluted in PBS with 3% BSA and 0.1% Tween–20 was added for 1 h, 
followed by three washes in PBS. Quantitative determination of bound Hsp90–CTD was done 
through the addition of the HRP–substrate reagent (DY999 – R&D), which contains 
tetramethylbenzidine (TMB) and H2O2. TMB acts as a hydrogen donor for the reduction of 
H2O2 to water, catalyzed by the HRP. After signal development, the reaction was stopped 
through the addition of 5N sulfuric acid, and the plates were read at 450 nm in a plate reader. 
For competition assays, Hsp90–CTD bound to immobilized Silibinin was challenged with 
Silibinin or Novobiocin in solution for 1 h at RT. Silibinin was dissolved to a final 
concentration of 1 mM in PBS with 1% BSA, 0.05% Triton X–100 and 5% DMSO. 
Novobiocin was dissolved to a final concentration of 6 mM in TBS with 0.05% Tween–20 
and constant 5% DMSO. All dilution series were done in the respective buffers. After three 
washes in PBS, the remaining bound Hsp90–CTD was detected with antibodies as described 
above. 
 
CO–IMMUNOPRECIPITATION OF THE GR::HSP90 COMPLEX 
Co–immunoprecipitation (CoIP) studies allow for the detection of protein–protein 
interactions. The isolation of protein I will result in detection of protein II, if they interact. 
Cellular lysate is incubated with anti–I antibody, and antibody is precipitated with magnetic 
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beads that are coated with recombinant protein G. Protein G is a high affinity binder of the 
immunoglobulin Fc–region. Precipitated complexes are attached to a magnet, which attracts 
the beads and allows for washing of the complexes. The complexes are then processed as for 
immunblot. Protein I and protein II are probed after SDS–PAGE and transfer onto a 
membrane. Using this method, it is possible to study whether two proteins interact with each 
other, and whether chemical compounds do influence this interaction. 
AtT–20 cells in culture were grown at 1 x 10
6
 per 10 cm dish for 48 h in cell culture medium, 
and an additional 48 h in cell culture medium with 2% FCS, washed and scraped in cold PBS. 
The cell pellets were pooled. Per dish, the cell pellet was dissolved in 150 µl TEDGM 
supplemented with complete protease inhibitor and sonicated twice with a microtip for 1 s at 
intermediate setting, followed by centrifugation for 15 min at 16.000g and 4°C. The 
supernatant was precleared with 10 µl per dish Dynabeads Protein G for 30 min rotating at 
4°C. Aliquots of the supernatant were incubated with increasing concentrations of Novobiocin 
dissolved in TEDGM with 0.1% Triton X–100 or Silibinin dissolved in TEDGM with 1% 
BSA and 0.05% Igepal–630 with constant 3% DMSO for 1 h at 4°C. Prior to drug incubation, 
the aliquots of the lysate were adjusted to 0.1% Triton X–100 for Novobiocin and 0.5% BSA 
and 0.05% Igepal–630 for Silibinin. The different compositions of the lysates did not 
significantly influence yield or unspecific precipitation as determined by a non–antibody 
control as well as rabbit IgG non–immune antibody. 2 µl per dish H–300 or 0.4 µg per dish 
PA3–013 antibody was added for 2 hours at 4°C. The immune complex was captured with 10 
µl per dish Dynabeads Protein G for 30 min at 4°C and washed 3 times with TEDGM with 
0.1% Tween–20, and once with TEDGM without detergent, followed by boiling in sample 
buffer and immunoblot. On the membrane, GR was detected with M–20 antibody, and Hsp90 
with H90–10 antibody. 
 
3
H–DEXAMETHASONE BINDING TO GR IN AtT–20 CELLS 
AtT–20 cells in cell culture medium with 10% stripped FCS were seeded at 2 x 10
5
 cells per 
well into 24–well plates and left to attach for 24 h. The medium was changed to cell culture 
medium with 0,1% stripped FCS and Silibinin was added at a concentration of 30 µM for 48 
h. Vehicle was kept at 0,2% DMSO. The medium was replaced by DMEM with increasing 
concentrations of tritiated Dexamethasone (
3
H–Dexamethasone) with or without a 500–fold 
excess of unlabelled Dexamethasone and incubated for 4 hours at 4°C. The ethanol 
concentration was kept constant at 0,5%. The cells were washed three times for five minutes 
with 500 µl cold PBS at 4°C. The cells were then lysed in 150 µl Passive Lysis buffer per 
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well, and the lysate was added to 3 ml scintillation fluid, vortexed an counted in a beta 
counter (Beckman LS6000IC). In parallel, control wells were trypsinized and counted. The 
data shown refers to counts per minute (cpm) per 1 mio cells for the Silibinin experiment, 
while in the 17–AAG experiment, the values represent cpm per well. Specific binding was 
calculated by subtraction of unspecific binding (in the presence of excess unlabelled 
Dexamethasone) from total binding. Maximal specific binding (Bmax) and the dissociation 
constant (Kd) was determined using nonlinear regression for single site saturation ligand 
binding as implemented in SigmaPlot. GR binding sites per cell were calculated from Bmax 
and the standard curve for input of 
3
H–Dexamethasone. The Scatchard plot was derived from 
specific binding divided by input (bound/free) plotted over specific binding. The values 
depicted for competition of 
3
H–Dexamethasone to GR with increasing concentrations of 
unlabelled Dexamethasone or the GR antagonist RU–38486 represent total binding. 
 
REPORTER ASSAYS 
Reporter gene assays investigate the transcriptional activity of a specific promoter region. It 
can provide the researcher with direct conclusions on the activity of the corresponding 
endogenous promoter, and thus, the mRNA produced by the downstream gene. As can be the 
case for quantitative RT–PCR, however, mRNA stability of the endogenous downstream gene 
does not play a role in reporter assays, since the promoter under investigation is fused to a 
reporter gene which introduces a ‘standardized’ mRNA. These assays can be a convenient 
tool to identify certain transcription factor response elements, and to study the impact of 
mutations thereof. It can be cotransfected with expression vectors for transcription factors of 
interest, dominant negative mutants thereof, or for cellular inhibitors of transcription factors. 
In the present study, reporter assays were used to determine the effects of endogenous or 
overexpressed GR on promoter activity under the influence of the Hsp90 inhibitors. 
The MMTV–Luc construct contains four GR response elements which are naturally contained 
in the long-terminal repeat sequence of the mouse mammary tumor virus (MMTV) 
(Hollenberg and Evans, 1988), fused to the luciferase reporter gene. This construct constitutes 
a very strong promoter for GR mediated transcriptional effects, and has been extensively used 
to study GR function. The TK–Luc is a minimal promoter (tyrosine kinase) fused to the 
luciferase promoter. The GRE2–TK-Luc contains two artificial consensus GR response 
elements (GRE) integrated upsteam of the TK minimal promoter (Rupprecht et al., 1993). 
Since this is an artificial construct with the GREs being the only regulatory binding sites, it 
can be used to study direct effects of GR without the influence of other (transcription) factors. 
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The POMC–Luc construct contains the 770 base pairs rat POMC promoter and includes all 
the sequences necessary for the expression and regulation of POMC in corticotroph cells (Liu 
et al., 1992). It was used here to investigate the role of GR as trans–repressor of Nur77 
(Philips et al., 1997b). The NurRE-Luc is a reporter which contains three copies of a Nur 
response element fused upstream of the POMC minimal promoter (Philips et al., 1997b), and 
this construct was used to confirm the results for POMC–Luc. The amount of luciferase 
transcribed from any reporter gene correlates with the conversion of luciferin to produce light 
during the measurement of cellular lysate in a chemiluminescent plate reader. In RSV–Gal, 
the Rous–Sarcoma Virus (RSV) promoter is a strong constitutive promoter which displays 
relatively little reactivity on a number of cellular stimuli. It is thus used as a control reporter 
to adjust for transfection efficiency between wells. The galactosidase reporter activity is 
measured by colorimetry at 405 nm after the enzyme’s conversion of synthetic o–
Nitrophenyl–β–D–galactopyranosid into galactose and the yellowish o–Nitrophenol. In all 
experiments, the luciferase values were divided by the galacatosidase values. 
AtT–20 cells in cell culture medium with 10% stripped FCS were seeded at 1 x 10
5
 cells per 
well into 24–well plates and left to attach for 24 h. Per well, 0.4 µg empty pcDNA3.1+ 
(Invitrogen), 0.3 µg reporter plasmid and 0.1 µg RSV–Gal were mixed with 40 µl DMEM and 
4 µl Superfect reagent. After 10 min at RT, 210 µl cell culture medium without FCS were 
added, and after washing the cells with PBS, 250 µl transfection mix was added for 3 h. The 
transfection mix was then replaced with cell culture medium without FCS ON. Treatment of 
the cells was done in cell culture medium with 2% stripped FCS and a constant DMSO 
concentration of 0.2%. After drug incubation, the cells were washed in cold PBS, and lysed in 
150 µl Passive Lysis buffer ON in –80°C. For galactosidase activity, 20 µl lysate was added 
to 30 µl aqua bidest. and mixed with 50 µl 2x ONPG buffer, followed by incubation at 37°C 
and measurement at 405 nm in a plate reader. For luciferase activity, 20 µl lysate were mixed 
with 50 µl luciferin in the TriStar (Berthold), followed by measurement of 
chemiluminescence. The final results are the ratio of luciferase/galactosidase to control for 
transfection efficiency between the wells. Graphs were done using Microsoft Excel. 
 
MUTAGENESIS 
We received the expression vector for rat GR from Dr. Simons Jr. (NIH – Bethesda, USA). 
To produce the P548A/T549A/V551A triple mutant (Kaul et al., 2002), the pSVLGR–WT 
plasmid was used for single–step mutagenesis with the QuikChange II XL site–directed 
Mutagenesis Kit. The forward mutagenesis primer was 5’–CCA CAG CTC ACC GCT GCC 
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TTG GCG TCA CTG–3’, and the reverse mutagenesis primer had the sequence 5’–CAG 
TGA CGC CAA GGC AGC GGT GAG CTG TGG–3’, with the mutated nucleotides 
underlined, and as depicted in the table. 
 
base pair (position)         C/G(1652) A/G(1655)   T/C(1662)     
sequence CCA CAG CTC ACC GCT GCC TTG GCG TCA TCG 
amino acid position P544 Q545 L546 T547 P548A T549A L550 V551A S552 L553 
Table M1: Summary of the mutagenesis. 
 
To introduce the mutations, 10 ng plasmid DNA was mixed 125 ng forward and reverse 
primer each, plus PCR reactants according to the manufacturer’s instructions. An initial cycle 
at 95°C for 30 min was followed by 18 cycles of: 95°C for 30 s; 55°C for 1 min; 68°C for 7.5 
min. Thereafter, 1 µl of DpnI endonuclease was incubated for 1 h at 37°C. DpnI cleaves 5’–
GA^TC–3’ only when the adenosine is methylated. Thus, the plasmid that was propagated in 
bacteria, and which is used for mutagenesis, will be digested. The linear, mutated amplicons 
will be preserved for further processing. 
The digested DNA (1 µl) was added to 50 µl E. coli XL1–blue and incubated on ice for 30 
min, followed by 45 s in a 42°C waterbath, and again 2 min on ice. 1 ml prewarmed NYZ+ 
medium was added, and the culture was put on a shaker for 1 h at 37°C (included in the kit). 
Then, 250 µl culture were plated on LB agar plates containing 50 µg ml
–1
 Ampicillin ON. 
To confirm successful mutagenesis, 6 clones were picked for propagation ON in LB medium 
with 50 µg ml
–1
 Ampicillin, and plasmids were purified using the Qiagen Mini–Prep kit. The 
plasmids were sent for sequencing at SequiServe (Vaterstetten, Germany), and all clones 
showed the desired base pair exchanges at positions 1652, 1655 and 1662 in comparison to 
the wildtype (WT) plasmid. 
For reporter gene assays with overexpressed GR, AtT–20 cells were transfected with 0.2 µg 
expression plasmid (WT or mutant), 0.2 µg pcDNA3.1+, and reporter as described above. 
Nonlinear regression was done using SigmaPlot. Treatment was done as described above. 
 
IMMUNOCYTOCHEMISTRY 
In order to investigate the subcellular localization of GR and Hsp90 upon treatment with the 
Hsp90 inhibitors and/or Dexamethasone, culture slides of AtT–20 cells were used for 
immunocytochemistry (ICC). 1 x 10
4
 cells per well in cell culture medium were seeded in a 
8–chamber slide and left to attach for 24 h. After that, medium was changed to cell culture 
medium with 0.1% FCS and cells were treated for 48 h with Silibinin or Novobiocin, or 15 
  42 
min with 17–AAG. The DMSO concentration was kept constant at 0.2%. Dex was added for 
the last 15 min. The medium was removed and the cells were fixed for 10 min at room 
temperature with PBS and 4% PFA (prepared freshly). After three washes in PBS, cells were 
permeabilized for 10 min at RT with 0.2% Triton X–100 in PBS, followed by blocking for 1 h 
at RT with PBS and 3% BSA. Antibody to GR (H–300 1:500) and antibody to Hsp90 (H90–
10 1:500) were diluted in blocking solution with 0.1% Tween–20 and incubated over night at 
4°C. After 3 washes in PBS, fluorophore conjugated secondary antibodies were diluted 1:500 
in blocking solution with 0.1% Tween–20 and incubated for 1 h at RT, followed by 3 washes 
in PBS. Cells were mounted in ProLong® antifade Gold which contains DAPI to counterstain 
for DNA, and covered with a cover slip. Slides were evaluated in a Zeiss Axioskop II 
connected to a mercury lamp through filters according to the fluorophores. 
 
RADIOIMMUNOSSAY OF ACTH 
In order to investigate ACTH secretion from AtT–20 cells and primary cultures of human 
corticotroph adenomas as well as normal rat pituitary cells, the ACTH radioimmunoassay 
(RIA) was performed. The assay procedure was modified in our laboratory and utilized in 
several published works (Paez-Pereda et al., 2001; Labeur et al., 2008; Giacomini et al., 2006; 
Reiter et al., 2011). ACTH standard is labeled with radioactive iodine by Chloramin T 
reaction. This method incorporates 
125
I into the single tyrosine residue in ACTH. The 
principle of this assay is based on the competition of ACTH in cell culture supernatant with a 
fixed concentration of labeled ACTH for an antibody directed against ACTH. The more 
ACTH in the cell supernatant, the less labeled ACTH binds to the fixed concentration of 
antibody. A secondary antibody is bound to the primary antibody to increase immunglobulin 
complex size. This large complex can be precipitated using polyethylene glycol buffer to 
separate specific residual 
125
I–ACTH bound to the antibody–complex from unbound 
125
I–
ACTH in solution. Radioactivity is measured in a gamma counter. A standard curve is 
included in each experiment, and an initial determination of the ACTH concentration in the 
samples is used to calculate the sample dilution range in order to be in the linear range of the 
standard curve. For labeling, ACTH–standard was diluted to 1 mg ml
–1
 in 0.01 M acidic acid 
and diluted 1:10 with phosphate buffer. 
125
I in phosphate buffer was mixed with Chloramin T 
and the reaction was stopped after 5 s with sodium disulfite. After seperation of labeled 
ACTH with silica gel, washing and elution, the 
125
I–ACTH stock (tracer) was frozen until 
further use. The standard curve was produced through serial dilutions of unlabeled ACTH (1 
mg ml
–1
) in DMEM to 10.000 – 5000 – 2500 – 1250 – 625 – 312 – 156 – 78 – 0 pg ml
–1
 and 
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incubation ON at 4°C with 20.000 – 25.000 cpm per 100 µl tracer and primary antibody 
directed against ACTH (in–house production). Secondary antibody (anti–rabbit IgG) was 
added for 1 h at RT. The complex was isolated with PEG buffer, and the pellet was counted in 
a Wizard 1470 gamma counter (Perkin Elmer). Figure M2 shows a typical standard curve. 
The abscissa depicts the concentration of the standard. On the ordinate, B/T stands for bound 
divided by total and is calculated for each value by the measurement of radioactivity for each 
concentration of standard used, minus the unspecific signal (primary antibody was omitted) – 
the value 0.1 represents 100% binding of tracer for 0 pg ml
–1
 standard, and the binding signal 
decreases with increasing concentrations of standard. The sample values calculated from the 
fitted regression curve correspond to pg ml
–1
. 
 
 
Figure M2: Representative example of the standard curve used in the RIA experiments. 
 
AtT–20 cells in stripped cell culture medium were seeded at 1 x 10
5
 cells per well into 24–
well plates and left to attach for 24 h. Cells were treated with Silibinin or 17–AAG for 24 h in 
cell culture medium with 0.1% stripped FCS. Thereafter, cells were washed in DMEM and 
treated for an additional 24 h with Silibinin or 17–AAG, and Dexamethasone in cell culture 
medium with 0.1% stripped FCS, and the supernatant was frozen for RIA. DMSO was kept 
constant at 0.2% for all conditions. 
After attachment, primary cultures of human corticotroph adenomas and normal rat pituitary 
cells were treated identical to AtT–20 cells as described above, except that the medium for rat 
normal pituiatry cells contained 1% stripped FCS and MEM vitamins. 
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AtT–20 ALLOGRAFT MODEL 
The Max Planck Institute of Psychiatry does not have the facilities to house immunodeficient 
mice. The animal studies, except for hormone measurement, were conducted by an external 
company. Immunodeficient male NMRI nude mice were injected unilateral subcutaneously 
with 30 µl AtT–20 cells dissolved in PBS at a concentration of 5 x 10
6
 per ml. After seven 
days, animals were randomized into vehicle (n = 12; 10 ml kg
–1
 day
–1
 aqua bidest.) and 
treatment group (n = 12; 300 mg kg
–1
 day
-1
 Silibinin (Silicur – Hexal) in aqua bidest.). 
Silibinin or vehicle was administered intraorally. Tumor volumes were determined every four 
days with a calliper. Blood samples were collected by cardiac puncture 24 h after the last 
treatment from isoflurane–anesthetized animals. 
RIA was utilized to measure plasma ACTH (ImmuChem
TM
 from MP Biomedicals) according 
to the manufacturer’s instructions, as well as plasma corticosterone (Rat/Mouse RIA from 
DRG Instruments). All animal experiments were conducted according to the guidelines of the 
German Animal Welfare Act. 
 
STATISTICAL ANALYSIS 
P<0.05 was considered statistically significant in two–tailed, unpaired Student’s t tests or 
Welch’s t test, or repeated measures ANOVA. For the allograft model in nude mice, the 
sample size of 12 animals was chosen because a strong effect size for the treatment on tumor 
growth and hormonal control was expected. Violations of parametric t test assumptions with 
5% significance threshold were tested. The Kolmogorov–Smirnov test was applied in order to 
analyze normality of data distribution in the samples, followed by f–testing to verify whether 
the assumptions of equal variances between groups was fulfilled. 
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6 RESULTS 
 
HSP90α IS OVEREXPRESSED IN BIOPSY SPECIMENS OF HUMAN CORTICOTROPH ADENOMAS 
Overexpression or increased activity of the Hsp90 chaperone machinery has been shown in 
numerous types of cancer. Since strongly reduced levels as well as overexpression of Hsp90 
impede GR signalling, it was hypothesized that the high threshold of agonist necessary to 
activate GR in corticotroph pituitary adenomas might be caused by aberrant expression and/or 
activity of Hsp90. Thus, as a basis to investigate this hypothesis, the expression level of the 
inducible Hsp90α isoform was determined by immunohistochemistry in biopsy specimens of 
human pituitary adenomas from patients with Cushing’s disease that have undergone 
transphenoidal surgery. For comparison, post–mortem normal human pituitary tissue was 
examined. 
As shown in Figure 1, strong overexpression of Hsp90α was evident in corticotroph adenomas 
from patients with Cushing’s disease (n = 12/14). A representative specimen for the strong, 
cytoplasmatic staining in the homogenous adenoma tissue is shown. The two remaining 
corticotroph adenoma specimens which were not scored as highly overexpressing Hsp90α had 
poorly conserved tissue structure, and were thus excluded. In contrast, the normal human 
pituitary tissue showed a typical, heterogeneous morphology with only single cells expressing 
Hsp90α at a detectable level (n = 6/6). These can be identified as corticotroph cells by their 
morphology, and they expressed Hsp90α at a much lower level than the adenomateous cells 
do. To address the question if overexpression of Hsp90α is specific for corticotroph 
adenomas, its abundance was compared to that in hormone insufficient pituitary adenomas. 
Staining of 14 non–functioning pituitary adenomas was additionally conducted. No 
overexpression was found in this malignancy (n = 14/14). Of note, as compared to normal 
pituitary, no single cells with detectable Hsp90α expression interspersed in the homogenous 
adenoma tissue were observed (Fig. 1). Therefore, Hsp90α overexpression was specifically 
found in corticotroph adenomas. 
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Figure 1: Immunohistochemistry of Hsp90α in cryosections. A representative example of a human 
corticotroph adenoma (CPA) from a patient with Cushing’s disease, a non–functioning pituitary 
adenoma (NFPA) from a patient with hormone insufficiency, or post–mortem normal human pituitary 
tissue (NP) is shown. Counterstaining for nuclei was done with toluidine blue, the Hsp90α signal is 
brown (DAB). Scale bars: 40µm. 
 
THE INHIBITION OF HSP90 WITH SMALL MOLECULES HAS ANTIPROLIFERATIVE EFFECTS 
IN AtT–20 CELLS 
In order to investigate the role of Hsp90 in corticotroph adenoma function, the well 
established corticotroph adenoma cell line AtT–20 was established. This cell line is derived 
from a mouse corticotroph adenoma, and it is the only available cellular model for Cushing’s 
disease – no human cell line is available. AtT–20 cells exhibit all endocrine features necessary 
to study the regulation of ACTH production: As in normal corticotroph cells, POMC is under 
control of the pituitary specific transcription factor Tpit, which acts in concert with Pitx 
(Lamolet et al., 2001). ACTH production is mainly enhanced by CRH, via downstream 
induction and activation of Nur77 (Kovalovsky et al., 2002). Basal and cAMP–induced 
ACTH–production is repressed through activated GR (Philips et al., 1997a; Philips et al., 
1997b). Thus, AtT–20 cells retain the status of differentiated corticotroph cells, however, their 
malignant characteristics can be exploited to investigate aspects of cell cycle control which 
are deregulated in corticotroph adenomas. 
To this end, three distinct Hsp90 inhibitors were chosen: the Geldanamycin derivative 17–
AAG, which targets the N–terminal ATPase domain of Hsp90. The C–terminal Hsp90 
inhibitor Novobiocin, and the recently discovered Hsp90 inhibitor Silibinin. As shown in 
Figure 2, the proliferation of AtT–20 cells is reduced in a dose dependent manner by each of 
the inhibitors after 96 h in culture (Fig. 2). 
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Figure 2: Antiproliferative effects of Hsp90 inhibitors. AtT–20 cells in culture were incubated with 
increasing concentrations of 17–AAG, Novobiocin, or Silibinin for 96 h, followed by determination of 
cell viability with the WST–1 assay. Shown are means ± s.d. Similar results were obtained for two 
replications of the experiments. 
 
DIFFERENTIAL EFFECTS OF HSP90 THE INHIBITORS ON CELL CYCLE 
Hsp90 integrates numerous signalling cascades which control survival and proliferation. To 
elucidate the mechanism by which the Hsp90 inhibitors exert their antiproliferative effects on 
AtT–20 cells, the cell cycle distribution was investigated in the presence of the different 
Hsp90 inhibitors. 17–AAG increased the hypodiploid population in a time– and dose–
dependent manner, which indicates apoptotic DNA fragmentation (Fig. 3a). In contrast, both 
Novobiocin (except for the highest dose) and Silibinin caused a pronounced arrest of AtT–20 
cells in the G2/M checkpoint of the cell cycle at 24 h. However at 48 h, AtT–20 cells treated 
with Novobiocin show increased cell death, and the G2/M population is lost. The clinically 
safe Hsp90 inhibitor Silibinin led to sustained arrest of AtT–20 cells in the G2/M checkpoint 
of the cell cycle also after 48–hour treatment, while no increase of apoptotic cells was 
observed except for the highest concentration (Fig. 3b and c). Therefore, different Hsp90 
inhibitors produce distinct cellular effects. 
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Figure 3: Cell cycle distribution of AtT–20 cells in the presence of Hsp90 inhibitors. Cell 
populations were determined by propidium staining and FACS analysis. The bar charts represent the 
percent change compared to control cells for increasing concentrations of each inhibitor. The bar 
charts and cell cycle profiles as depicted in the histogram to the right (□ control or ■ compound) were 
derived from raw data as described under Materials & Methods. (a) Effects of 17–AAG (0.25–0.5–1–
1.5–3 µM) and after 48–hour treatment with 1.5 µM for the histogram. (b) Effects of Novobiocin (50–
75–100–150–300 µM) and after 48–hour treatment with 150 µM for the histogram. (c) Effects of 
Silibinin (5–10–20–40–60 µM) and after 48–hour treatment with 40 µM for the histogram. The results 
shown are representative of three (17–AAG and Novobiocin) or four (Silibinin) independent 
experiments. 
 
DIFFERENTIAL EFFECTS OF HSP90 THE INHIBITORS ON CLIENT PROTEIN STABILITY 
A hallmark of the pharmacologic inhibition of Hsp90 is the degradation of client proteins. 
Due to the pronounced cell cycle arrest that is caused by the treatment of AtT–20 cells with 
Silibinin and Novobiocin, the cellular protein level of the central mediator of mitotic 
progression, Cdc2, was determined. Cdc2 is a prominent Hsp90 client protein (Garcia-
Morales et al., 2007; Nakai and Ishikawa, 2001). As shown in Figure 4a, all inhibitors tested 
led to the degradation of Cdc2 with increasing concentrations after 48–hour treatment. The 
protein level of Hsp90α was not influenced by the compounds (Fig. 4a). 
Due to the important physiological role that the GR plays in the suppression of ACTH in 
corticotroph cells, its protein level was investigated. As was shown for Geldanamycin 
(Whitesell and Cook, 1996; Segnitz and Gehring, 1997), the N–terminal Hsp90 inhibitor 17–
AAG caused the degradation of GR. In sharp contrast, neither Novobiocin nor Silibinin 
influenced the cellular GR protein level. This is the first report that different Hsp90 inhibitors 
have diverging effects on the cellular fate of distinct classes of Hsp90 client proteins (Fig. 
4a). 
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It was reported that Geldanamycin and derivates readily cross the cell membrane and that they 
show immediate effects of Hsp90 inhibition. Time course experiments were done to 
investigate when the inhibitors proved activity. As shown in Figure 4b, 17–AAG exhibited 
effects on the cellular Cdc2 and GR protein level already 3 h after the start of drug incubation. 
Novobiocin and Silibinin had detectable effects starting at 6 h, with strong effects from 12 h 
onwards. Again, neither Silibinin nor Novobiocin had an effect on GR protein levels at any 
time point (Fig. 4b). 
 
 
Figure 4: Investigation of the effects of Hsp90 inhibitors on client protein stability. (a) AtT–20 
cells were treated for 48 h with the indicated Hsp90 inhibitors (µM), followed by SDS–PAGE and 
protein detection by immunoblot with antibodies to Cdc2, GR, Hsp90α, and β–Actin. (b) AtT–20 cells 
were treated with 5 µM 17–AAG, 200 µM Novobiocin or 60 µM Silibinin for the indicated periods of 
time, and cellular protein was determined as in a. Each experiment was repeated at least twice (17–
AAG) or three times (Novobiocin and Silibinin), with similar outcomes. 
 
SILIBININ BINDS TO THE C–TERMINAL DOMAIN OF HSP90 IN A REVERSIBLE MANNER 
The observation that Silibinin and Novobiocin caused G2/M arrest and did not impact cellular 
GR protein levels at concentrations of active and specific Hsp90 inhibition – as shown by 
degradation of Cdc2 – led to the hypothesis that both inhibitors share the same molecular 
mechanism. Therefore, it is likely that they bind to the same domain in Hsp90. Due to the 
results obtained with trypsin nicking, protein truncation experiments and molecular 
modelling, it has been proposed that Novobiocin binds to a cavity in the C–terminal domain 
(CTD) of Hsp90 (Yun et al., 2004; Marcu et al., 2000a; Matts et al., 2011). However, it has 
never been shown that Silibinin binds to the CTD of Hsp90. To this end, the fact that small 
molecule compounds can be immobilized on a polystyrene surface to detect its interaction 
with purified recombinant Hsp90–CTD was exploited (Morra et al., 2010). As shown in 
Figure 5a, recombinant human Hsp90–CTD (amino acids 566–732 of human Hsp90α) 
(Young et al., 2003) could be detected after incubation on immobilized Silibinin. The binding 
curve followed a sigmoidal pattern, i.e. at the lowest concentrations minimal Hsp90 binding 
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was detectable, and the binding was saturated at the highest concentrations (Fig. 5a). 
Importantly, Hsp90–CTD bound to immobilized Silibinin could be challenged by excess 
Silibinin and Novobiocin in solution. Furthermore, the incubation of increasing 
concentrations of Hsp90–CTD with a constant concentration of immobilized Silibinin (64 
µM) also resulted in a binding curve in which the input concentration highly correlated with 
the observed binding signal (Fig. 5b). 
The highest concentration of Silibinin used in the competition assay did not completely 
reverse Hsp90–CTD binding. Higher concentrations precipitated after high speed 
centrifugation of the working solution, and resulted in irreproducible artifacts in the binding 
assay, namely a variable increase in Hsp90–CTD signal as opposed to specific competition of 
lower Silibinin concentrations (data not shown). In contrast, the formulation of Novobiocin 
used in this work (Novobiocin sodium salt) is water soluble, thus, solubility was not a limiting 
factor. The highest concentrations fully competed Hsp90–CTD binding to immobilized 
Silibinin (see Fig. 5a). Together, these results suggested that Silibinin and Novobiocin share 
an identical or overlapping binding motif on the CTD of Hsp90. 
 
 
Figure 5: Binding of recombinant human Hsp90–CTD to Silibinin. (a) Increasing concentrations 
of Silibinin immobilized to a polystyrene surface were incubated with 3 µg ml
–1
 of Hsp90–CTD, 
followed by ELISA. Bound Hsp90–CTD was challenged with Silibinin or Novobiocin in solution. (b) 
64 µM Silibinin were immobilized and incubated with increasing concentrations of Hsp90–CTD. Data 
in a and b show means ± s.d. of representative results of at least three independent experiments 
(*P≤0.05, **P≤0.01; compound vs. control). 
 
THE C–TERMINAL HSP90 INHIBITORS SILIBININ AND NOVOBIOCIN DISSOCIATE THE 
GR::HSP90 COMPLEX IN VITRO 
After binding, Novobiocin forces Hsp90 into a conformation that releases client proteins and 
leads, for example, to the dissociation of the client heme–regulated eIF2α kinase (Yun et al., 
2004). Therefore, using co–immunoprecipitation, it was investigated here whether the C–
terminal Hsp90 inhibitors Silibinin and Novobiocin dissociate the GR::Hsp90 complex in 
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AtT–20 cell lysates. It was found that either compound disrupted this complex in a 
concentration dependent manner, both when GR or Hsp90α were immunoprecipitated (Fig. 
6). 
 
 
Figure 6: Effects of Silibinin and Novobiocin on the GR::Hsp90 complex. Cellular lysate of AtT–
20 cells was incubated with the indicated concentrations of Hsp90 inhibitor at 4°C, followed by 
precipitation of GR or Hsp90α using specific antibodies (NI – non–immune rabbit IgG; IP – 
immunoprecipitation; IB – immunoblot). 
 
SILIBININ INCREASES 
3
H–DEXAMETHASONE BINDING TO GR IN AtT–20 CELLS 
Earlier studies showed that GR requires dynamic interactions with Hsp90 to maintain its high 
affinity binding conformation (Dittmar et al., 1997), and that N–terminal Hsp90 inhibitors 
impair steroid binding (Whitesell and Cook, 1996; Segnitz and Gehring, 1997; Morishima et 
al., 2000). To determine whether GR loses steroid binding activity in the presence of 
Silibinin, we characterized its effects on 
3
H–Dexamethasone binding to GR in AtT–20 cells. 
The cells were incubated with 
3
H–Dexamethasone at 4°C following inhibitor treatment, since 
low temperature traps cellular processes, and it is thus possible to investigate the binding 
characteristics of GR at a particular moment (i.e. complexed to Hsp90 in the absence of 
inhibitor vs. dissociated from Hsp90 in the presence of inhibitor) without the influence 
cellular events which rapidly follow agonist binding (Galigniana et al., 2001; Czar et al., 
1997). Unexpectedly, it was observed that Silibinin increased the number of GR sites (control: 
36,240 ± 588 receptors per cell vs. Silibinin: 58,740 ± 1,855 receptors per cell) that bind 
3
H–
Dexamethasone with high affinity (control: Kd = 2.77 ± 0.37 nM vs. Silibinin: Kd = 2.49 ± 
0.28 nM) (Fig. 7a), indicating that GR is fully mature after Silibinin treatment. Increasing 
concentrations of unlabeled Dexamethasone as well as the selective GR antagonist RU–38486 
displaced the binding of 
3
H–Dexamethasone (Fig. 7b). Furthermore, 15–minute treatment 
with 17–AAG prior to the addition of 
3
H–Dexamethasone obliterated the high–affinity 
binding state of GR (Fig. 7c). This is in line with previous works that short term treatment 
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with Geldanamycin abolishes the steroid binding activity of GR prior to detectable 
degradation (Whitesell and Cook, 1996). The results show that the test system used here 
reflects specific binding of 
3
H–Dexamethasone to GR in AtT–20 cells and the dependence of 
GR steroid binding activity on Hsp90. 
Therefore, Silibinin caused the release of mature GR from Hsp90, so that more receptors are 
available in the cell to bind steroid with high affinity. 
 
 
Figure 7: Binding of 
3
H–Dexamethasone to GR in AtT–20 cells. (a) The effects of 30 µM Silibinin 
on the steroid binding activity of GR. Specific binding (left) is calculated from total minus unspecific 
(right) 
3
H–Dexamethasone (
3
H–Dex) binding. The Scatchard plot is derived from specific 
3
H–Dex 
binding in cpm (B/F – bound/free). (b) Competition of binding of 5 nM 
3
H–Dex by increasing 
concentrations of unlabelled Dexamethasone (Dex) or RU–38486 (**P≤0.01; residual binding of 
3
H–
Dex alone vs. 
3
H–Dex plus competitor). (c) Effects of 17–AAG on GR binding activity (**P≤0.01). 
Data in a–c show means ± s.d. from representative experiments, each replicated twice. 
 
THE C–TERMINAL HSP90 INHIBITORS SILIBININ AND NOVOBIOCIN POTENTIATE THE 
TRANSCRIPTIONAL ACTIVITY OF GR IN AtT–20 CELLS 
In order to investigate the effects of Hsp90 inhibition on GR function, reporter gene assays 
were performed. AtT–20 cells were transiently transfected with the GR–responsive MMTV–
Luc construct. Figure 9a shows the effects of 48–hour incubation with the indicated Hsp90 
inhibitor. Dexamethasone was added for the last 18 h. The N–terminal Hsp90 inhibitor 17–
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AAG dose dependently abolished GR activity, which is in line with the receptor degradation 
that was previously observed (see Figure 4). In sharp contrast, both Silibinin and Novobiocin 
potentiated the transcriptional activity elicited by Dexamethasone. This effect was dose–
dependent and saturable, and neither inhibitor showed effects on MMTV–Luc activity in the 
absence of Dexamethasone (Fig. 8a). 
The enhancing effect Silibinin and Novobiocin was also observed after pretreatment for 24 h 
and the addition of Dexamethasone for 6 h, except that the enhancement of GR activity by the 
compounds was less pronounced (Fig. 8b). Under these conditions, either of the two 
inhibitors increased GR activity to that elicited by a 10–fold higher concentration of 
Dexamethasone alone, whereas after 48 h treatment, the combination of C–terminal Hsp90 
inhibitor plus Dexamethasone increased GR activity above that observed with a 10–fold 
higher concentration of Dexamethasone alone (see Fig. 8a). When AtT–20 cells were treated 
for 6 h and Dexamethasone was added for further 3 h, only a minimal enhancement of GR 
activity was observed for the highest concentration of Silibinin or 200 µM Novobiocin, while 
300 µM Novobiocin showed a slight suppression of GR activity (Fig. 8c). For comparison, 
Silibinin and Novobiocin also showed weak effects of Hsp90 inhibition at short incubation 
times as measured by the stability of Cdc2 (see Fig. 4b). 
To confirm that the effects of Silibinin are indeed mediated specifically by GR, the synthetic 
GR antagonist RU–38486 was used. As shown in Figure 8d, the induction of MMTV–Luc by 
Dexamethasone was abolished in the presence of RU–38486. The potentiation of GR activity 
in the presence of Silibinin plus Dexamethasone was equally abolished in the presence of the 
antagonist (Fig. 8d). 
Furthermore, when AtT–20 cells were transfected with a construct containing the minimal 
TK–promoter with two GR response elements fused upstream (GRE2–TK–Luc), Silibinin 
potentiated the stimulation induced by Dexamethasone. In contrast, when a reporter construct 
which lacks the GR response elements upstream of the TK–promoter was transfected (TK–
Luc), neither Dexamethasone nor Dexamethasone plus Silibinin induced its activity (Fig. 8e). 
Together, these results show that the effects of Silibinin do not cause an unspecific increase of 
transcription on the reporter genes. The inhibition of Hsp90 with Silibinin specifically 
potentiates the activity of GR elicited by its agonist. 
 
  54 
 
Figure 8: Determination of GR activity in AtT–20 cells using reporter gene assays. (a) Effects of 
48–hour treatment with the indicated Hsp90 inhibitors on MMTV–Luc activity. Dex was added for the 
last 18 h; shown are means ± s.d. of one representative experiment (n = 4 total). (b) Effects of 24–hour 
treatment with the indicated Hsp90 inhibitors on MMTV–Luc activity. Dex was added for the last 6 h; 
shown are means ± s.d. (n = 2 experiments). (c) Effects of 6–hour treatment with the indicated Hsp90 
inhibitors on MMTV–Luc activity. Dex was added for additional 3 h; shown are means ± s.d. (n = 2 
experiments). (d) AtT–20 cells were treated as in a, with the exception that Dex and RU–38486 were 
added as indicated for the last 6 h; shown are means ± s.d. of one of two independent experiments. (e) 
AtT–20 cells were transiently transfected with TK–Luc or GRE2–TK–Luc and treated for 48 h with 
Silibinin. Dex was added for the last 18 h; shown are means ± s.d. of fold change to control cells for 
two independent experiments (*P≤0.05, **P≤0.01; compound plus Dex vs. Dex alone). AU stands for 
arbitrary units. 
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ALTERED INTERACTION BETWEEN A GR MUTANT AND HSP90 INTERFERES WITH THE 
EFFECTS OF SILIBININ 
Due to the findings that C–terminal Hsp90 inhibitors promote the exit of GR from the 
chaperone in order to fulfil its role as a transcription factor in the presence of ligand, it was 
hypothesized here that a mutant of GR that displays altered interaction with Hsp90 would be 
influenced by Silibinin to a lesser extent than WT–GR. 
To test this notion, the triple mutant P548A/T549A/V551A (AAA) of rat GR (Kaul et al., 
2002) was overexpressed in AtT–20 cells. Silibinin showed a strong enhancing effect on WT–
GR, while the mutant was minimally affected, and this effect was most obvious at half–
maximal activity of each construct. As reported (Kaul et al., 2002), the mutant displayed a 
greatly reduced hormone responsiveness compared to WT (Fig. 9). The MMTV–Luc values 
gained for the activity of endogenous GR in a parallel control experiment (mock transfection) 
were below 15% of those measured for overexpressed WT–GR. Due to possible unspecific 
effects, higher concentrations of Dexamethasone were considered to not contribute additional 
valuable information. 
 
 
Figure 9: Effects of Silibinin on overexpressed WT and mutant GR. AtT–20 cells were treated for 
48 h with Silibinin and Dex was added for the last 18 h. Maximal activity was set to the highest 
concentration of Dex applied (right); shown are means ± s.d. of one representative experiment (n = 2). 
 
THE RAPID TRANSPORT OF AGONIST BOUND GR REMAINS FUNCTIONAL IN THE PRESENCE 
OF C–TERMINAL HSP90 INHIBITORS 
The dependence of activated GR (holo–GR) on Hsp90 for the rapid and controlled nuclear 
transport was demonstrated (Czar et al., 1997). Since the reporter assays used here involved 
prolonged exposure to Dexamethasone (6 and 18 h), diffusion of GR into the nucleus might 
have taken place in the presence of the C–terminal Hsp90 inhibitors, which could still have 
resulted in the observed potentiation of GR activity. In order to investigate the effects of 
Hsp90 inhibitors on the rapid transport of holo–GR into the nucleus, immunocytochemistry 
was performed in AtT–20 cells. Figure 10 shows representative examples of nuclear 
  56 
accumulation of GR after 15 min exposure to 10 nM Dexamethasone with or without 
pretreatment of the Hsp90 inhibitors. For AtT–20 cells which were pretreated for 15 min with 
17–AAG, the staining of GR remained diffuse in the presence of Dexamethasone, reflecting 
inhibition of Hsp90 which hampers the transport of holo–GR into the nucleus as was reported 
for Geldanamycin (Czar et al., 1997). In contrast, after 48–hour treatment with Silibinin or 
Novobiocin, the nuclear accumulation of GR upon short exposure to Dexamethasone was 
comparable to that observed for control treated cells, while each inhibitor alone did not 
significantly influence the cellular localization of GR (Fig. 10). Thus, neither C–terminal 
inhibitor interferes with the molecular mechanism of Hsp90 which is necessary for the 
directed transport of activated GR into the nucleus. 
 
 
Figure 10: Nuclear transport of GR. AtT–20 cells were for 15 min with 10 µM 17–AAG, or for 48 h 
with 30 µM Silibinin or 100 µM Novobiocin. Dex was added for additional 15 min, cells were fixed 
and stained with DAPI. GR and Hsp90 were detected with specific antibodies and visualized using 
fluorescence microscopy. 
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SILIBININ ENHANCES THE SUPPRESSION OF ACTH MEDIATED BY GR IN AtT–20 CELLS 
GR suppresses both basal and CRH–induced production of ACTH through trans–repression 
of the orphan receptor Nur77 in corticotroph cells as a monomer to recruit HDAC2, thus 
shutting down POMC gene expression (Philips et al., 1997b; Bilodeau et al., 2006). This 
molecular mechanism is different from trans–activation, in which binding of a GR dimer to 
GR response elements in the target genes recruits coactivators for the enhancement of gene 
expression. The fact that Silibinin potentiates GR trans–activation (MMTV–Luc and GRE2–
TK–Luc) led to the attractive notion that it might also enhance the suppression of endogenous 
ACTH in corticotroph adenoma cells. If this was the case, the partial Gc–resistance observed 
in patients with Cushing’s disease could potentially be relieved by this small molecule. 
First, this notion was investigated at the transcriptional level. AtT–20 cells were transiently 
transfected with the NurRE–Luc minimal construct or the POMC–Luc construct. These 
reporters contain three repeats of a Nur response element upstream of the POMC minimal 
promoter (Philips et al., 1997b), or the 770 bp of the rat POMC promoter and thus includes all 
the necessary sequences for the expression of POMC in pituitary cells in vivo (Liu et al., 
1992), fused to luciferase, respectively. While Silibinin did not show effects on the basal 
activity of either reporter, the suppression of transcription elicited by low doses of 
Dexamethasone were potentiated for both constructs (Fig. 11a). 
Next, it was investigated whether the effects of Silibinin on POMC activity resulted in a 
reduction of secretion of ACTH from AtT–20 cells. Therefore, AtT–20 cells in culture were 
treated for 48 h in medium containing 0.1% FCS to minimize effects of proliferative 
differences between the control and Silibinin treated cells. It was determined beforehand that 
– under these conditions – AtT–20 cells exhibit a normal cellular shape (see Fig. 10), that they 
hardly proliferate (WST–1), and that they do not show apoptotic DNA fragmentation (FACS) 
after 48 h (data not shown). In the experiments here, following hormone measurement, 
random wells were trypsinized and viable cells were determined by acridine orange/ethidium 
bromide staining followed by cell counting in a Neubauer counting chamber to confirm that 
the cell number did not significantly differ between the conditions (control: 5.1 ± 0.5 x 10
5
 
cells ml
–1
 vs. 40 µM Silibinin: 4.8 ± 0.6 x 10
5
 cells ml
–1
). Figure 11b shows that Silibinin did 
not influence basal ACTH production as measured by radioimmunoassay (RIA). However, 
the minimal suppression of ACTH by 1 nM Dexamethasone, which did not reach 
significance, was dose dependently enhanced by Silibinin. 10 nM Dexamethasone achieved a 
slight but significant suppression of ACTH, and this suppression was again potentiated by 
Silibinin (Fig. 11b). 
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For direct comparison, the effects of the N–terminal Hsp90 inhibitor 17–AAG on ACTH 
production in AtT–20 cells was investigated (Fig. 11c). There was a dose dependent reduction 
of basal ACTH secreted into the supernatant after 48 h of treatment. Notably, low 
concentrations of 17–AAG did not abolish suppression of ACTH mediated by GR. The 
highest dose of 17–AAG did not alter ACTH production when Dexamethasone was co–
incubated, which likely reflects the observation that 17–AAG abolishes GR function at this 
concentration (see Fig. 8a). 
In sum, it was confirmed that Silibinin results in the increased suppression of POMC 
transcription that is mediated by GR. As a consequence, the production of ACTH was 
significantly reduced when Dexamethasone was combined with Silibinin compared to 
Dexamethasone alone. 
 
SILIBININ RESTORES GLUCOCORTICOID SENSITIVITY IN PRIMARY CULTURES OF HUMAN 
CORTICOTROPH ADENOMAS 
It was next sought to confirm that the molecular mechanism of Silibinin is also active in 
human corticotroph pituitary adenomas. To this end, primary cultures of biopsies from 
patients with Cushing’s disease that had undergone transphenoidal surgery were produced. 
Figure 11d shows that 48 h treatment with 40 µM Silibinin did not have an effect on basal 
ACTH–production. However, the suppression elicited by 10 nM Dexamethasone during the 
last 24 h was variably, but significantly enhanced by Silibinin in 5 out of 6 specimens (Fig. 
11d). Thus, Silibinin could potentially restore Gc–sensitivity in human corticotroph 
adenomas. 
 
SILIBININ DOES NOT SHOW EFFECTS IN PRIMARY CULTURES OF RAT NORMAL PITUITARY 
CELLS 
Silibinin is reported to have an outstanding safety profile in animals and humans, with only 
mild adverse side effects even at high doses. It was investigated whether Silibinin treatment 
would influence normal corticotroph function, or permanently destroy normal pituitary 
viability: Apoptotic cells spill the storage vesicles filled with ACTH into the supernatant and 
result in strongly increased measurements. To this end, primary cultures from rat anterior 
pituitary were produced. RIA was performed to investigate the effects of Silibinin on ACTH 
production. Figure 11e shows that a concentration of Silibinin two–fold higher than that 
which elicited maximal effects in the corticotroph adenoma cells did not influence basal 
production or Dexamethasone suppression of ACTH (Fig. 11e). 
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Figure 11: Effects of Hsp90 inhibitors on the regulation of POMC and ACTH production. (a) 
Treatment of AtT–20 cells for 48 h with Silibinin, with Dex added for the last 6 h. Normalized 
NurRE–Luc and POMC–Luc activity for control cells was set to 100%. (b) Silibinin and (c) 17–AAG 
differentially impact ACTH secretion in AtT–20 cells as measured by RIA. (d) Silibinin potentiates 
the suppression of ACTH mediated by GR in primary cultures of human corticotroph adenomas. Data 
in a–d show means ± s.d. Results in a–c are representative of three to five independent experiments 
(*P≤0.05, **P≤0.01; compound plus Dex vs. Dex alone). (e) Silibinin does not affect GR activity in 
primary cultures of normal rat pituitary cells. Shown are means ± s.d. (*P≤0.05, **P≤0.01; Dex vs. 
control). 
 
SILIBININ SHOWS ANTITUMORIGENIC EFFECTS IN A MOUSE ALLOGRAFT MODEL FOR 
CUSHING’S DISEASE 
AtT–20 cells produce tumors when injected subcutaneously into immunocompromised mice 
(Leung et al., 1982; Paez-Pereda et al., 2001). This model was used to determine the in vivo 
antitumorigenic efficacy of Silibinin. Daily administration of 300 mg Silibinin per kg 
bodyweight to male nude mice (n = 12 each group) implanted with AtT–20 allografts 
significantly reduced tumor growth as compared to the vehicle treated group after 28 days of 
treatment (Fig. 12a). Repeated measures ANOVA revealed that  
Patients with Cushing’s disease exhibit abnormal accumulation of central fat (moon face, 
buffalo hump) and tend to become obese (Feelders et al., 2012). Some of the phenotypical 
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symptoms observed in humans also display in hypercortisolemic mice which were implanted 
with AtT–20 cells (Leung et al., 1982). Symptoms which displayed in the mice were 
alleviated by Silibinin treatment as shown by the reduction in abnormal accumulation of fat 
deposits, and the less obese phenotype. Of note, the tumor of the Silibinin treated animal 
showed necrosis (Fig. 12b). The body weight of mice in the treatment group was lower 
compared to that of the vehicle group, but the difference did not reach significance. 
The reduction in symptoms was paralleled by the enhanced suppression of plasma hormone 
levels by Silibinin. Measurement of ACTH and Corticosterone (Cort) levels showed an 
enhancing effect of Silibinin on the suppression of ACTH in the presence of high levels of 
circulating Corticosterone. In the treatment group, both ACTH and Corticosterone were 
reduced to approximately one third of the level observed in the vehicle treated group (Fig. 
12c). Naïve animals without tumor (n = 3) and treatment served as control. 
Taken together, these results reflect the in vivo efficacy of Silibinin. Furthermore, it was 
demonstrated that the molecular mechanism of Silibinin that was observed in vitro also is 
active in a mouse allograft model for Cushing’s disease. 
 
 
Figure 12: Effects of Silibinin in an allograft model for Cushing’s disease in mice. (a) Seven days 
after AtT–20 cell injection, animals were randomized into vehicle (n = 12) and treatment group (n = 
12). Suppression of the mean tumor volume ± s.e.m. in NMRI mice with AtT–20 tumor allografts by 
daily treatment of 300 mg Silibinin per kg body weight as compared to vehicle treatment (repeated 
measures ANOVA; **P<0,05). (b) Symptoms of representative animals in the vehicle and treatment 
group. Arrows denote abnormal fat pads which were reduced in the group that received Silibinin. 
Arrowheads point to the tumor. (c) Box plots of plasma ACTH and Corticosterone levels 24 h after the 
last treatment (Welch’s t test; **P≤0.05; Silibinin vs. vehicle). 
Note: Housing of the mice, feeding and drug administration, tumor injection, randomization, 
determination of tumor volume, and blood sampling were conducted by a third party, not by the 
author of the present work. 
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7 DISCUSSION 
 
Patients with Cushing’s disease suffer from chronic hypercortisolism which is caused by 
excessive secretion of ACTH from partially Gc–resistant corticotroph pituitary adenomas. To 
elucidate the molecular mechanism which underlies the partial Gc–resistance, genetic screens 
revealed that mutations of GR only explain the reduced hormone responsiveness in sporadic 
cases (Lamberts, 2002). Determination of the expression of the non–steroid binding isoform 
of GR could not explain the aberrant GR activity (Dahia et al., 1997). Brg–1 and HDAC2, 
cofactors of the transcriptional complex of GR necessary to suppress POMC were found to be 
abnormally expressed in less than half of the corticotroph adenomas investigated (Bilodeau et 
al., 2006). Hence, the molecular basis of the partial Gc–resistance of corticotroph adenomas is 
incompletely understood. 
In the present work, it was hypothesized that abnormal expression or activity of the molecular 
chaperone Hsp90, the direct regulator of GR activity, causes the reduced sensitivity to Gcs in 
corticotroph adenoma cells. It was shown that human corticotroph adenomas strongly 
overexpress Hsp90α. Using distinct classes of Hsp90 inhibitors, strong antiproliferative 
effects and normalization of the response to Gcs were observed, indicating that Hsp90 
overexpression is a pathogenic mechanism in corticotroph adenomas. These effects were 
explained by degradation of the oncogenic client protein Cdc2 with a concomitant cell cycle 
arrest, apoptotic DNA fragmentation, and the release of mature GR from Hsp90. The 
clinically safe Hsp90 inhibitor Silibinin enhanced the suppression of ACTH mediated by GR 
in AtT–20 cells and in primary cultures of human corticotroph adenomas. This explained the 
partial reversal of hormonal changes by treatment with the C–terminal Hsp90 inhibitor in the 
mouse allograft model for Cushing’s disease, in addition to its antitumorigenic effects in vivo. 
In contrast, Silibinin did not affect the function of GR in rat normal pituitary cells. 
 
THE SELECTION PROCESS OF THE HSP90 INHIBITORS 
The benzoquinone ansamycin Geldanamycin was the first N–terminal Hsp90 inhibitor 
discovered (Whitesell et al., 1994). While it enabled researchers to gain insights into the 
function of Hsp90, it resulted in severe liver toxicity in a preclinical model (Supko et al., 
1995). The toxicity of quinones is caused by their ability to produce reactive oxygen species 
due to redox cycling, as well as reacting with thiols to produce glutathione conjugates and 
adducts with cellular proteins (Guo et al., 2008). Due to its promising activity as anticancer 
agent in vitro, Geldanamycin served as the parent compound of 17–AAG, a first generation 
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Hsp90 inhibitor with greatly diminished intrinsic toxicity that proceeded to clinical phase II 
studies. After Geldanamycin showed severe cellular toxicity in AtT–20 cells even at 
concentrations when Hsp90 inhibition was not complete, it was decided to pursue further 
experiments with 17–AAG. It was a valuable process to observe the difference between a lead 
compound and a first generation derivative – at pronounced inhibition of Hsp90, the cells did 
not display signs of unspecific, toxic effects. 
The aminocoumarin antibiotic Novobiocin is a C–terminal Hsp90 inhibitor. When cell cycle 
distribution was investigated in AtT–20 cells, Novobiocin caused an arrest at the G2/M phase 
at 24 h of treatment, whereas an increase in cells in subG1 phase was observed after 48–hour 
treatment. Silibinin, the second C–terminal Hsp90 inhibitor, arrested AtT–20 cells caused a 
G2/M arrest also at 48 h. This difference may be explained by unspecific, toxic effects of 
Novobiocin on AtT–20 cells. Indeed, a steep dose–response curve in the cell viability assay 
(WST–1 assay) suggests that this small molecule has intrinsic physicochemical properties 
which elicit cytotoxicity independent of its molecular target. This notion was corroborated 
when AtT–20 cells showed clear signs of toxicity under treatment with Novobiocin at 
concentrations higher than 500 µM. The majority of cells round up and detached from the 
culture plate within hours. Acridin orange/ethidium bromide staining revealed significant 
membrane disruption prior to morphological signs of controlled cell death. Furthermore 
Novobiocin showed an increase in apoptotic cells at the highest concentration used. In 
contrast, concentrations of 17–AAG which completely inhibit Hsp90 did not result in 
increased uptake of ethidium bromide, and the cells progressively displayed a distinct 
morphology which indicates apoptosis (i.e. normal morphology was preserved until 
membrane blebbing occurred, followed by cell death). 
It is known that Novobiocin in high concentration binds to the N–terminal ATP binding 
pocket of Hsp90 in addition to the C–terminal domain (S+Âti et al., 2002), hence possibly 
acting like an N–terminal Hsp90 inhibitor. This notion may apply for the effects observed for 
two different assays in which 300 µM Novobiocin were used to treat AtT–20 cells. After 24 h, 
an increase in apoptotic cells was observed for the FACS analysis, an effect which is similar 
to that seen for 17–AAG. Also, 300 µM Novobiocin inhibited GR activity after 6 h, while 
lower concentrations increase GR activity. 
The flavonoid Silibinin shows an outstanding safety profile in rodents as well as humans, 
even when high doses are administered (Saller et al., 2001; Hawke et al., 2010; Flaig et al., 
2010). Depending on the formulation, Silibinin is readily adsorbed to reach plasma 
concentrations in the range of pharmacologic activity, ≥ 30µM in humans (Flaig et al., 2010). 
  63 
Unfortunately, it is quickly conjugated in the liver for secretion (Wu et al., 2008). Silibinin 
has shown anticancerogenic effects in numerous types of cancer both in vitro and in vivo. 
Although not stated by the authors, seemingly pleiotropic effects of this small molecule led to 
the disruption of cancer pathways, mainly via targeted degradation of oncogenic kinases 
(Ramasamy and Agarwal, 2008). The evidence that the effects of Silibinin on cancer cells can 
be explained by the inhibition of Hsp90 is strong: Cell cycle arrest, the induction of apoptosis, 
or the inhibition of angiogenic processes were caused through the degradation of Cdk2, Cdk4, 
Cdc2 and Cdc25, WT– and mutant EGFR, Akt, Raf–1, IKK, MMP–2 and MMP–9, and HIF–
1α (Dastpeyman et al., 2012; Rho et al., 2010; Tai et al., 2008; Ting et al., 2013). All of these 
proteins are prominent clients of Hsp90 and they display high sensitivity to its pharmacologic 
inhibition. Investigating two well–defined, endogenous Hsp90 clients in the cellular model 
AtT–20, where they fulfil physiologically relevant tasks, we found that Silibinin led to well 
defined effects which can be ascribed to the specific inhibition of Hsp90. 
Additionally, Silibinin has been found to be effective in treating hepatic injury due to bile 
duct inflammation, cirrhosis, fatty liver, and mushroom poisoning (Pradhan and Girish, 2013). 
Consistent with the effects elicited by other flavonoids, Silibinin augments cellular 
antioxidant mechanisms involving glutathione and superoxide dismutase to scavenge free 
radicals, which could in part explain its effectiveness to prevent the induction of lipid 
peroxidation and cell death under certain pathologic conditions (Ligeret et al., 2008). Since 
the inhibition of Hsp90 using N–terminal inhibitors disrupts antioxidant mechanisms (De–
Raedt et al., 2011), the diverging observations regarding this protective pathway may be 
attributed to distinct effects elicited by the C–terminal vs. N–terminal Hsp90 inhibitors, or by 
off–target effects of high concentrations of Silibinin. 
It has been proposed that Silibinin is a selective ERβ agonist (Seidlov–Wuttke et al., 2003). 
However, additional reports showed contradicting results, stating that Silibinin either has 
estrogenic effects or anti–estrogenic effects in ovariectomized rats (Seidlov–Wuttke et al., 
2003; Pliskova et al., 2005; Kummer et al., 2008). Longitudinal feeding studies over up to two 
years in rats and mice showed equal survival between groups, similar growth rates as well as 
body weight gain. Female mice did not display with estrous cycle abnormalities when fed 
with Silibinin, and a significant reduction of spontaneously formed mammary tumors was 
observed (Dunnick et al., 2011). Hence, it is unlikely that Silibinin elicits estrogenic effects. 
Considering that Silibinin may be efficacious in restoring the sensitivity of corticotroph 
adenomas to Gcs, this notion is of importance for the possibility of long term treatment of 
patients with Cushing’s disease. 
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DIVERGING EFFECTS OF THE HSP90 INHIBITORS ON CELL CYCLE AND CLIENT PROTEIN 
STABILITY 
The anticancerogenic potential of Hsp90 inhibitors is based on the degradation of client 
proteins that drive oncogenesis and survival (Jhaveri et al., 2012). In order to be valuable as 
anticancer drugs, it was believed that all classes of Hsp90 inhibitors must act in the same way 
– the degradation of client proteins, which of course includes oncoproteins. In the corticotroph 
adenoma cell line AtT–20, the three distinct Hsp90 inhibitors 17–AAG, Silibinin and 
Novobiocin showed antiproliferative activity. However, diverging effects on cell cycle 
distribution were observed. While the N–terminal Hsp90 inhibitor 17–AAG caused an 
increase in hypodiploid cells, which is indicative of apoptotic DNA fragmentation, the C–
terminal Hsp90 inhibitors Silibinin and Novobiocin arrested AtT–20 cells in the G2/M 
checkpoint of the cell cycle. Since all inhibitors led to the degradation of the Hsp90 client 
kinase Cdc2, an arrest at the G2/M checkpoint would have been expected also for 17–AAG. 
However, the rapid proteasomal degradation of most, if not all, proteins which require Hsp90 
for function is observed in the presence of N–terminal Hsp90 inhibitors (Trepel et al., 2010). 
This may lead to the induction of apoptotic pathways that are dominant over cell cycle arrest, 
as was observed in AtT–20 cells. The molecular mechanism elicited by C–terminal Hsp90 
differs from that of N–terminal Hsp90 inhibitors. Hsp90 bound to N–terminal inhibitors is 
isolated in cryptic, non–functional complexes with cochaperones that inefficiently binds to 
client proteins, which results in their degradation (An et al., 2000; Thulasiraman and Matts, 
1996; Taipale et al., 2012). In contrast, the binding of C–terminal inhibitors results in a 
conformational change which reflects the client release conformation of Hsp90 with respect to 
kinases and cochaperones (Yun et al., 2004; Marcu et al., 2000a). These observations were 
confirmed in the present work, since both Silibinin and Novobiocin led to the release of 
mature GR from Hsp90 without influencing its cellular protein level, while 17–AAG caused 
the rapid loss of steroid binding activity of GR, followed by its degradation. Such functional 
differences between the two classes of Hsp90 inhibitors may cause the observed cell cycle 
arrest due to the predominant degradation of Cdc2 in the presence of Silibinin or Novobiocin 
in AtT–20 cells, which is only then followed by apoptosis. 
 
THE DEPENDENCE OF CDC2 ON HSP90 IN CORTICOTROPH ADENOMA CELLS 
Upon inhibition of Hsp90, AtT–20 cells displayed with cell cycle arrest at the G2/M phase 
due to the degradation of Cdc2, suggesting a particular role for the pathway of the cyclin–
dependent kinase in corticotroph adenoma cells. This notion is corroborated by the fact that 
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pituitary adenoma formation is frequently observed in mice which lack the universal cyclin–
dependent kinase (Cdk) inhibitor p27
Kip1 
(Nakayama et al., 1996). 
A recent work described the degree of dependence of client proteins on Hsp90, both with 
respect to their interaction, as well as their sensitivity to pharmacologic inhibition and 
subsequent degradation (Taipale et al., 2012). Using their assay, Cdc2 did not seem to be a 
client protein of Hsp90, which is in apparent contrast to the results obtained here and previous 
works (Nakai and Ishikawa, 2001; Garcia-Morales et al., 2007). Nakai et. al showed that 
when cellular Hsp90α levels were reduced, specific destabilization of Cdc2 was observed 
even under very mild heat stress (Nakai and Ishikawa, 2001). It can therefore be assumed that 
the overexpression of Hsp90α – as was observed in human corticotroph adenomas – leads to 
increased stability of this kinase, potentially driving oncogenic transformation. It is a well 
known fact that cancer cells with increased Hsp90 expression display with excessive 
stabilization of oncogenic client proteins, and thus, entire pathways (Whitesell and Lindquist, 
2005). In turn, clients which are highly expressed, or increasingly unstable due to mutations, 
display enhanced dependence on Hsp90 (Xu et al., 2005; Patel et al., 2013). A cellular 
pathway driven by an oncogenic client protein is extremely susceptible to pharmacologic 
inhibition of Hsp90, unequivocally through the degradation of the client protein driving it. 
The degree to which a certain type of cancer is affected through the pharmacologic inhibition 
of Hsp90 is reflected by its dependence on this specific oncogenic pathway (Moulick et al., 
2011; Patel et al., 2013; Isaacs et al., 2003). In corticotroph adenoma cells, Hsp90 inhibition 
results in the degradation of the oncogenic kinase Cdc2. Also the GR, which regulates ACTH 
production in normal corticotroph cells, and which is characterized by a partial resistance in 
corticotroph adenoma cells, is strongly affected by the inhibition of Hsp90. 
 
C–TERMINAL HSP90 INHIBITORS ELICIT A NOVEL MOLECULAR MECHANISM WHICH 
LEADS TO THE DISSOCATION OF MATURE GR FROM HSP90 
Observations made in which GR is artificially dissociated from Hsp90 in cellular lysate 
(increase in temperature, ionic strength, pH, dilution) have shown that GR cannot bind to Gcs 
under these conditions (Bresnick et al., 1989). Surprisingly, Silibinin and Novobiocin trigger 
the release of GR from the Hsp90 complex. Inside the living cell, this results in an increase of 
mature GR that keeps its high affinity for Dexamethasone, thus potentiating hormone 
responsiveness. 
There are no reports on the action of Silibinin on GR signaling. However, our results with 
Novobiocin are in contrast to two earlier studies, in which higher concentrations inhibited the 
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maturation of GR in RRL and targeted it for degradation in Hela–cells (Kanelakis et al., 2002; 
Allan et al., 2006). This discrepancy is explained by the fact that Novobiocin in high 
concentrations binds to Hsp70 (Kanelakis et al., 2002) and to the N–terminal ATP binding 
pocket of Hsp90, in addition to the more sensitive C–terminal binding site (Söti et al., 2002) 
involved in the effects we report here. 
Evidence that the effects of Silibinin on GR activity are due to the inhibition of Hsp90 is 
provided by the AAA–mutant of rat GR which was overexpressed in AtT–20 cells. The 
P548A/T549A/V551A mutations are located in a heptapeptide inside helix 1 at the very N–
terminus of the GR–LBD (Bledsoe et al., 2002), and the presence of this motif is essential for 
the interaction of GR with Hsp90 (Xu et al., 1998). The mutant GR is activated to the same 
level as WT–GR in mammalian cells, however, it requires higher concentrations of 
dexamethasone to be activated (Kaul et al., 2002). Kaul et al. have shown that altered 
interaction of the AAA–mutant with Hsp90 leads to the observed reduction in steroid binding 
activity when this protein complex is in its dynamic state, i.e. within the cytoplasm of a living 
cell. If, in contrast, the AAA–mutant was matured by the five protein assembly system in 
vitro, which forces a stable GR::Hsp90 complex, it exhibits the same steroid binding activity 
as WT–GR (Kaul et al., 2002). Thus, the mutations do not abolish the ability of the GR–LBD 
to undergo structural changes necessary to acquire the high–affinity steroid binding 
conformation or its ability to act as a transcription factor, and constitute an appropriate model 
to investigate the effects of C–terminal Hsp90 inhibitors. 
If the effects of Silibinin were not via inhibition of Hsp90, once activated, the activity of the 
AAA–mutant should be influenced similarly to that of WT–GR. While the AAA–mutant 
displayed with strongly reduced hormone responsiveness in AtT–20 cells, which is in line 
with previous observations (Kaul et al., 2002), Silibinin minimally affected its activity. This 
was expected if Silibinin influences ineffective interaction between the mutant and Hsp90. In 
contrast, WT–GR was strongly affected by Silibinin treatment, which is in line with the 
finding that Silibinin reliefs the inhibitory effect of Hsp90 on endogenous GR. 
 
C–TERMINAL HSP90 INHIBITORS POTENTIATE GR ACTIVITY IN CORTICOTROPH ADENOMA 
CELLS 
As was shown in a series of two control experiments, the potentiation of transcriptional 
activity through C–terminal Hsp90 inhibitors required GR which was bound to 
Dexamethasone: Addition of the synthetic GR antagonist RU–38486 abolished the effects of 
Dexamethasone alone and in combination with Silibinin. Furthermore, the activity of the 
  67 
artificial GRE2–TK–Luc construct was potentiated when Silibinin was incubated in addition 
to Dexamethasone, while neither Dexamethasone alone or in combination with Silibinin 
showed an effect on the TK–Luc construct which lacks the GR response elements. 
The drug concentrations used to determine the effects on the transcriptional activity of GR 
were chosen according to the active inhibition of Hsp90 as determined by protein stability of 
Cdc2 and the absence of signs of cellular toxicity or a significant increase in apoptotic cells 
for all timepoints (FACS). The MMTV–Luc assay showed maximal effects for Silibinin and 
Novobiocin after 48 h of treatment. With respect to hormone responsiveness, the molecular 
mechanism elicited by this class of Hsp90 inhibitors is mainly due to its effects on apo–GR: 
Hsp90 has inhibitory activity on GR prior to Dexamethasone binding in corticotroph adenoma 
cells. The incubation with Silibinin or Novobiocin increasingly reliefs the inhibitory aspects 
of Hsp90 on GR over time. No effect was observed on MMTV–Luc activity when the 
compounds were incubated for 6 h, and Dexamethasone was added for additional 3 h. The 
addition of Dexamethasone leads to rapid conformational changes in GR, and the holo–
GR::Hsp90 complex is distinct from the apo–GR::Hsp90 complex. With respect to the rapid, 
Hsp90–dependent translocation of holo–GR into the nucleus, C–terminal did not influence the 
interaction between GR and Hsp90 which follows binding of Dexamethasone. The effects of 
Hsp90 inhibition by these compounds after short incubation is minimal, as is reflected by the 
protein stability of Cdc2 at that time point. However, when AtT–20 cells were treated for 24 h 
with the C–terminal inhibitors, and Dexamethasone was subsequently added, their effects on 
MMTV–Luc activity were significant. For comparison, the degradation of Cdc2 was complete 
at that and at later timepoints. When Silibinin or Novobiocin was incubated for 30 h prior to 
the addition of Dexamethasone, a pronounced potentiation of GR activity was observed. This 
explains the similar effects of Silibinin and Novobiocin, because Dexamethasone was added 
at a timepoint when both inhibitors led to the G2/M arrest, which is specific for the inhibition 
of Hsp90 with this class of small molecules in AtT–20 cells. 
The finding that C–terminal Hsp90 inhibitors potentiate the activity of GR through a 
mechanism that targets Hsp90 was corroborated by the fact that Silibinin also enhances the 
trans–repression of Nur77, and thus, POMC transcription. This consequently results in the 
reduction of ACTH in AtT–20 cells and in primary cultures of human corticotroph adenomas 
by Silibinin. 
The mechanism of Hsp90 action on GR maturation in corticotroph adenoma cells is different 
from – and might act in addition to – the dissociation of transcriptional complexes through 
Hsp90 in other cell types (Kang et al., 1999; Freeman and Yamamoto, 2002), as well as other 
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mechanisms that contribute to glucocorticoid–resistance in corticotroph adenoma cells, such 
as the down–regulation of cofactors of GR or mutations in GR (Bilodeau et al., 2006; Kino et 
al., 2003). In the present work, while Silibinin enhanced the effects of Dexamethasone on 
ACTH production in the majority of primary cultures from human corticotroph adenomas, 
one culture out of six did not react on Dexamethasone, or on the combination of 
Dexamethasone plus Silibinin. It is possible that such mechanisms are responsible for the 
complete absence of GR activity, as was observed in this adenoma. 
 
FUNCTIONAL ASPECTS OF HSP90 OVEREXPRESSION IN CORTICORTOPH ADENOMA CELLS 
How can the inhibition of Hsp90 with C–terminal inhibitors target the kinase Cdc2 for 
degradation, while the GR is not affected at the cellular protein level, and released from 
Hsp90 in a mature state that binds Dexamethasone with high affinity? First, GR and kinases 
interact with distinct domains in Hsp90 during the catalytic cycle, and they require different 
cochaperones (Fang et al., 2006; Vaughan et al., 2006; Grad and Picard, 2007). 
Furthermore it is possible that the overexpression of endogenous Hsp90 in corticotroph 
adenoma cells directs the composition of the Hsp90–cochaperone complexes into a direction 
which can efficiently fold and stabilize kinase clients – thereby driving tumorigenesis – but 
which may exert the observed inhibitory effects on the function of GR. Cochaperones 
ultimately regulate client recruitment as well as the catalytic cycle of Hsp90 (Röhl et al., 
2013). Dynamic changes in the composition of Hsp90–cochaperone complexes due to the 
overexpression of certain components of the chaperone machinery result in impaired activity 
of nuclear hormone receptors in particular (Davies et al., 2005; Laenger et al., 2009; Schuelke 
et al., 2010). Intriguingly, certain post–translational modifications enhance the ATPase 
activity of Hsp90, which results in disturbed capacity to chaperone client proteins, including 
GR (Mollapour et al., 2014). Similar observations were made when the catalytic cycle of 
Hsp90 was accelerated through overexpression of Aha1 (Wang et al., 2006). 
Hence, if the stoichiometry of Hsp90 and cochaperones can influence the conformational 
flexibility which constitutes the catalytic cycle of Hsp90, overexpression of Hsp90 may 
influence client protein fate to a similar extent than mutations in Hsp90. All mutations 
identified in Hsp90 are detrimental with respect to the chaperoning of client proteins. Isolated 
were point mutants of Hsp90 which cannot bind ATP (Panaretou et al., 1998), which bind 
ATP but show weak hydrolase activity (Xu et al., 2012), mutants that prevent post–
translational modifications (Retzlaff et al., 2009; Mollapour et al., 2010; Mollapour et al., 
2014), or those selected for reduced ability to sustain yeast cell viability as well as client 
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protein function under ambient or elevated temperature (Bohen and Yamamoto, 1993; Nathan 
and Lindquist, 1995; Hawle et al., 2006). It can be concluded that mutations in Hsp90 either 
interfere with the necessary conformational flexibility of the chaperone, that they distort 
motifs which may be required for client and/or cochaperone binding, or that the ATPase 
activity is abolished. While mutations constitute stable changes in a protein, the 
overexpression of Hsp90 can be targeted by small molecule compounds. In corticotroph 
adenoma cells, C–terminal Hsp90 inhibitors influence the function or the conformation of 
Hsp90. This results in the relief of inhibitory effects of Hsp90 on the maturation of GR 
without influencing its transport to the nucleus, while Cdc2 is targeted for degradation. On the 
other hand, Silibinin does not alter GR activity in normal pituitary cells. The tumor selectivity 
of Hsp90 inhibitors depends on hyperactive Hsp90α complexes in other malignancies (Kamal 
et al., 2003; Moulick et al., 2011). The absence of effects of Silibinin in normal pituitary cells 
may be explained by the low expression levels of Hsp90α. 
 
INTERPRETATION OF THE AtT–20 ALLOGRAFT MOUSE MODEL 
The allograft mouse model study was designed and conducted based on previous experience 
and reports with respect to the expected effect size, unilateral allograft injection, the start of 
treatment prior to the detectable formation of tumors (Leung et al., 1982; Paez-Pereda et al., 
2001), and drug dosage (Vogel et al., 1975). After 29 days of treatment, animals in the vehicle 
group uniformly presented with severe symptoms caused by the hypercortisolism, and it was 
decided to sacrifice the mice in order to be able to collect blood samples for hormone analyses 
from all animals in both groups 24 h after the last treatment. The reduction in allograft tumor 
volume as well as plasma hormone levels was significant in the animals which received 
Silibinin, which coincided with a relief of Cushingoid symptoms. By definition, a partial 
biochemical control of plasma or – more commonly – urinary free cortisol levels in patients 
with Cushing’s disease is defined by a ≥ 50% reduction to baseline (Colao et al., 2012). In the 
present study, Silibinin achieved this goal when the treatment group was compared to the 
vehicle group. Nevertheless, the hormonal levels in the Silibinin group were still strongly 
elevated compared to those measured in naïve control animals which received no treatment. 
The procedure of the oral drug administration could, in part, have contributed to the increased 
stress hormone levels in the study animals. Furthermore, the rapid clearance from the 
organism, or the tumors, may have hampered the efficacy of Silibinin in the allograft mouse 
model. In a human phase II clinical trial for patients with prostate cancer, Silibinin did not 
reach significant concentrations inside the tumors, which explained the absence of its effects 
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(Flaig et al., 2010). While the effects of Silibinin were strong in the mouse allograft model 
presented here, more favorable formulations of Silibinin that result in high plasma levels may 
achieve a biochemical control of patients with Cushing’s disease in the future. 
 
CONCLUSION 
In the present work, a pathogenic mechanism is described in which the strong overexpression 
of Hsp90α in corticotroph adenoma cells exerts inhibitory effects on GR for the binding of 
Gcs (Fig. IV – 1), and that this inhibitory mechanism is reversible using small molecules 
which target the C–terminal client binding domain of Hsp90 (Fig. IV – 2). The novel 
biochemical activity elicited by Silibinin and Novobiocin involve the release of mature GR 
from Hsp90, such that more receptor is available in the cell to bind Gcs with high affinity. 
Since C–terminal Hsp90 inhibitors the binding of Gcs to GR, both trans–activation and trans–
repression are enhanced. Through the increased suppression of ACTH mediated by GR, 
Silibinin reverses the partial Gc–resistance in human corticotroph adenomas. In normal 
corticotroph cells, GR senses physiological Gc–levels and Hsp90α shows low expression. In 
this cell type, the function of GR remains unaffected by the inhibitor (Fig. IV – 3). All 
together, it is shown that the clinically safe Hsp90 inhibitor Silibinin could be used to treat 
patients with Cushing’s disease. 
 
 
Figure IV: Summary of the effects of Hsp90 overexpression on GR activity in corticotroph adenomas 
and the potential restoration of Gc–sensitivity with C–terminal Hsp90 inhibitors. 
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